

FILE 'REGISTRY' ENTERED AT 09:07:15 ON 16 JUN 2008

L1 STRUCTURE UPLOADED
L2 50 S L1
L3 76450 S L1 SSS FULL
L4 STRUCTURE UPLOADED
L5 STRUCTURE UPLOADED
L6 STRUCTURE UPLOADED
L7 42345 S L4 SUB=L3 FULL
L8 9767 S L5 SUB=L7 FULL
L9 3925 S L6 SUB=L8 FULL

FILE 'CAPLUS' ENTERED AT 09:17:01 ON 16 JUN 2008

L10 1698 S L9

FILE 'STINGUIDE' ENTERED AT 09:17:10 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:18:05 ON 16 JUN 2008

L11 122010 S MONOSACCH? OR (BUILDING BLOCK) OR (LIBRARY)
L12 196 S L10 AND L11
L13 160 S L12 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'REGISTRY' ENTERED AT 09:22:10 ON 16 JUN 2008

L14 STRUCTURE UPLOADED
L15 337 S L14 SUB=L9 FULL
L16 3588 S L9 NOT L15

FILE 'HCAPLUS' ENTERED AT 09:23:09 ON 16 JUN 2008

L17 1520 S L16
L18 142 S L17 AND L13

FILE 'REGISTRY' ENTERED AT 09:25:30 ON 16 JUN 2008

L19 STRUCTURE UPLOADED
L20 726968 S L19 SSS FULL
L21 1328 S L19 SUB=L16 FULL
L22 2260 S L16 NOT L21

FILE 'HCAPLUS' ENTERED AT 09:27:22 ON 16 JUN 2008


L23 752 S L21
L24 96 S L18 AND L21

FILE 'REGISTRY' ENTERED AT 09:30:37 ON 16 JUN 2008

L25 STRUCTURE UPLOADED
L26 50 S L25
L27 7 S L26 SUB=L2 FULL
L28 0 S L22 NOT L7
L29 2260 S L22 NOT L27

FILE 'HCAPLUS' ENTERED AT 09:34:05 ON 16 JUN 2008

L30 872 S L29
L31 19 S L24 AND L29



G1 O,S
G2 C,S
G3 O,S,N
G4 C,O,S,N
G5 OH, [G1], [G2]

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 09:07:41 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 14980 TO ITERATE

13.4% PROCESSED 2000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 292268 TO 306932

PROJECTED ANSWERS: 72399 TO 79797

L2 50 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 09:07:47 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 303311 TO ITERATE

100.0% PROCESSED 303311 ITERATIONS

76450 ANSWERS

SEARCH TIME: 00.00.05

L3 76450 SEA SSS FUL L1

=> log hold

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

178.36

178.57

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 09:07:56 ON 16 JUN 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAEXO1623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 09:15:08 ON 16 JUN 2008
FILE 'REGISTRY' ENTERED AT 09:15:08 ON 16 JUN 2008
COPYRIGHT (C) 2008 American Chemical Society (ACS)

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

=>

=>

Uploading C:\Documents and Settings\eolson\My Documents\e-Red
Folder\10524048\10524048alkoxy.str

L4 STRUCTURE UPLOADED

=>

Uploading C:\Documents and Settings\eolson\My Documents\e-Red
Folder\10524048\10524048amino.str

L5 STRUCTURE UPLOADED

=>

Uploading C:\Documents and Settings\eolson\My Documents\e-Red
Folder\10524048\10524048hydroxy.str

L6 STRUCTURE UPLOADED

=> s l4 sub=13

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full
FULL SUBSET SEARCH INITIATED 09:16:22 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 74996 TO ITERATE

100.0% PROCESSED 74996 ITERATIONS

42345 ANSWERS

SEARCH TIME: 00.00.01

L7 42345 SEA SUB=L3 SSS FUL L4

=> s l5 sub=17

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full
FULL SUBSET SEARCH INITIATED 09:16:39 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 10196 TO ITERATE

100.0% PROCESSED 10196 ITERATIONS

9767 ANSWERS

SEARCH TIME: 00.00.01

L8 9767 SEA SUB=L7 SSS FUL L5

=> s 16 sub=18

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full

FULL SUBSET SEARCH INITIATED 09:16:53 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 9767 TO ITERATE

100.0% PROCESSED 9767 ITERATIONS

3925 ANSWERS

SEARCH TIME: 00.00.01

L9 3925 SEA SUB=L8 SSS FUL L6

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

306.04

306.25

FILE 'CAPLUS' ENTERED AT 09:17:01 ON 16 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jun 2008 VOL 148 ISS 25

FILE LAST UPDATED: 15 Jun 2008 (20080615/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 19

L10 1698 L9

=> file stnguide

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.48

306.73

FILE 'STNGUIDE' ENTERED AT 09:17:10 ON 16 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jun 13, 2008 (20080613/UP).

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.12

306.85

FILE 'HCAPLUS' ENTERED AT 09:18:05 ON 16 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jun 2008 VOL 148 ISS 25
FILE LAST UPDATED: 15 Jun 2008 (20080615/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s monosacch? or (building block) or (library)

25485 MONOSACCH?
133674 BUILDING
269519 BLOCK
8086 BUILDING BLOCK
(BUILDING(W)BLOCK)
88814 LIBRARY

L11 122010 MONOSACCH? OR (BUILDING BLOCK) OR (LIBRARY)

=> s l10 and l11

1698 L9
L12 196 L10 AND L11

=> s l12 and (PY<2003 or AY<2003 or PRY<2003)

22930220 PY<2003
4482946 AY<2003
3958496 PRY<2003

L13 160 L12 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> file stnguide

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 2.69 | 309.54 |

FILE 'STNGUIDE' ENTERED AT 09:18:11 ON 16 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 13, 2008 (20080613/UP).

<-----User Break----->

=> d l13 1-20 ti

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

- L13 ANSWER 1 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Preparation of oligosaccharide uronates, corresponding to fragments of natural mucopolysaccharides, and their biological applications
- L13 ANSWER 2 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
TI KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
- L13 ANSWER 3 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Tetrahydropyran compounds that interact with G protein-coupled receptors (GPCRs)
- L13 ANSWER 4 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
TI KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
- L13 ANSWER 5 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Synthesis of monosulfated saccharides in the spacers form
- L13 ANSWER 6 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
TI D-Glucose as a multivalent chiral scaffold for combinatorial chemistry
- L13 ANSWER 7 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Synthesis of tools for raising antibodies against moenomycin epitopes and initial immunological studies
- L13 ANSWER 8 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Combinatorial libraries of glucosamine monosaccharides
- L13 ANSWER 9 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
TI "Meshed-Bag Gathered-Bunch" Method for Solid-Phase Synthesis of Small Molecular Diverse Compounds
- L13 ANSWER 10 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
TI New efficient route for synthesis of lipid A by using affinity separation
- L13 ANSWER 11 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Linear Synthesis of a Protected H-Type II Pentasaccharide Using Glycosyl Phosphate Building Blocks
- L13 ANSWER 12 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Synthesis of a building block for phosphonate analogs of moenomycin A12 from D-tartaric acid
- L13 ANSWER 13 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Study of glycosylation with N-trichloroacetyl-D-glucosamine derivatives in the syntheses of the spacer-armed pentasaccharides sialyl lacto-N-neotetraose and sialyl lacto-N-tetraose, their fragments, and analogues
- L13 ANSWER 14 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Synthesis of the Fully Phosphorylated GPI Anchor Pseudohexasaccharide of Toxoplasma gondii
- L13 ANSWER 15 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
TI DISAL glycosyl donors for efficient glycosylations under acidic conditions: Application to solid-phase oligosaccharide synthesis

L13 ANSWER 16 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Aptamers that bind to the antibiotic moenomycin A

L13 ANSWER 17 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Substrate Specificity of the Glycosyl Donor for Oligosaccharyl Transferase

L13 ANSWER 18 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Methods for solid phase synthesis of α -D-Gal-(1,3)-Gal-containing oligosaccharides


L13 ANSWER 19 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Chemoenzymatic-chemical synthesis of a (2-3)-sialyl T threonine building block and its application to the synthesis of the N-terminal sequence of leukemia-associated leukosialin (CD 43)

L13 ANSWER 20 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Preparation of oligosaccharide lipid-A analogs as antitumor and immunostimulating agents

=> d l13 1-10 ti abs bib hitstr
 YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L13 ANSWER 1 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Preparation of oligosaccharide uronates, corresponding to fragments of natural mucopolysaccharides, and their biological applications

GI



I

AB The invention relates to a process for the organic synthesis of oligosaccharides constituting or comprising fragments of acid mucopolysaccharides comprising the reaction of two compds. constituted or terminated by units of glucosamine structure and of uronic acid structure resp., said units being specifically substituted. This process particularly enables valuable anticoagulant drugs to be obtained. Mucopolysaccharide fragments were synthesized. Thus the pentasaccharide I was prep'd from the monosaccharides in a synthesis comprising many steps. I has factor Xa antagonist activity >2000 U/mg.

AN 2008:603607 HCAPLUS <<LOGINID:20080616>>

DN 148:517928


TI Preparation of oligosaccharide uronates, corresponding to fragments of natural mucopolysaccharides, and their biological applications

IN Petitou, Maurice; Jacquinet, Jean-Claude; Sinay;; Pierre; Choay;; Jean;
 Lormeau;; Jean-Claude; Nassr;; Mahmoud
 PA Choay SA, Fr.
 SO U.S., 84pp., Cont. of U.S. Ser. No. 457,931, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 6

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|--------------|
| PI | US 4818816 | A | 19890404 | US 1987-115593 | 19871026 <-- |
| | FR 2504535 | A1 | 19821029 | FR 1981-8472 | 19810428 <-- |
| | FR 2504535 | B1 | 19870814 | | |
| | FR 2519987 | A1 | 19830722 | FR 1982-621 | 19820115 <-- |
| | FR 2520744 | A1 | 19830805 | FR 1982-1575 | 19820201 <-- |
| | FR 2521566 | A1 | 19830819 | FR 1982-2526 | 19820216 <-- |
| | AU 8283955 | A | 19821124 | AU 1982-83955 | 19820428 <-- |
| | AU 558472 | B2 | 19870129 | | |
| | JP 58500564 | T | 19830414 | JP 1982-501461 | 19820428 <-- |
| | JP 03013240 | B | 19910222 | | |
| | FR 2527614 | A1 | 19831202 | FR 1982-9392 | 19820528 <-- |
| | FR 2528853 | A1 | 19831223 | FR 1982-10891 | 19820622 <-- |
| | FR 2528854 | A1 | 19831223 | FR 1982-10892 | 19820622 <-- |
| | FR 2529557 | A1 | 19840106 | FR 1982-11679 | 19820702 <-- |
| | FR 2531436 | A1 | 19840210 | FR 1982-13804 | 19820806 <-- |
| | FR 2533219 | A1 | 19840323 | FR 1982-15803 | 19820920 <-- |
| | FR 2533220 | A1 | 19840323 | FR 1982-15804 | 19820920 <-- |
| | FR 2535324 | A1 | 19840504 | FR 1982-18003 | 19821027 <-- |
| | US 4987223 | A | 19910122 | US 1982-453731 | 19821027 <-- |
| | US 4607025 | A | 19860819 | US 1982-451615 | 19821220 <-- |
| | SU 1470196 | A3 | 19890330 | SU 1982-3528900 | 19821227 <-- |
| | DK 8205756 | A | 19821228 | DK 1982-5756 | 19821228 <-- |
| | DK 8300143 | A | 19830716 | DK 1983-143 | 19830114 <-- |
| | DK 174348 | B1 | 20021223 | | |
| | SU 1694065 | A3 | 19911123 | SU 1983-3545151 | 19830114 <-- |
| | AU 8321285 | A | 19840522 | AU 1983-21285 | 19831027 <-- |
| | AU 581167 | B2 | 19890216 | | |
| | JP 59501906 | T | 19841115 | JP 1983-503432 | 19831027 <-- |
| | JP 05066392 | B | 19930921 | | |
| | AT 40555 | T | 19890215 | AT 1983-402109 | 19831027 <-- |
| | DK 8403135 | A | 19840627 | DK 1984-3135 | 19840627 <-- |
| | DK 175970 | B1 | 20051003 | | |
| | US 4943630 | A | 19900724 | US 1986-856855 | 19860421 <-- |
| PRAI | FR 1981-8472 | A | 19810428 | <-- | |
| | FR 1982-621 | A | 19820115 | <-- | |
| | FR 1982-1575 | A | 19820201 | <-- | |
| | FR 1982-2526 | A | 19820216 | <-- | |
| | FR 1982-9392 | A | 19820528 | <-- | |
| | FR 1982-10891 | A | 19820622 | <-- | |
| | FR 1982-10892 | A | 19820622 | <-- | |
| | FR 1982-11679 | A | 19820702 | <-- | |
| | FR 1982-13804 | A | 19820806 | <-- | |
| | FR 1982-15803 | A | 19820920 | <-- | |
| | FR 1982-15804 | A | 19820920 | <-- | |
| | FR 1982-18003 | A | 19821027 | <-- | |
| | US 1982-451615 | A2 | 19821220 | <-- | |
| | US 1983-457931 | A1 | 19830114 | <-- | |
| | FR 1981-24132 | A | 19811223 | <-- | |
| | WO 1982-FR76 | A | 19820428 | <-- | |
| | FR 1982-18001 | A | 19821027 | <-- | |
| | EP 1983-402109 | A | 19831027 | <-- | |


WO 1983-FR217 A 19831027 <--
 US 1984-624628 A 19840626 <--
 OS MARPAT 148:517928
 IT 26922-15-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of oligosaccharide uronats, corresponding to fragments of
 natural mucopolysaccharides, and their biol. applications)
 RN 26922-15-6 HCAPLUS
 CN α -D-Glucopyranoside, phenylmethyl 2-deoxy-2-
 [[(phenylmethoxy)carbonyl]amino]-3-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




IT 69892-44-0P 85193-92-6P 87907-06-0P
 87907-35-5P 87907-36-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of oligosaccharide uronats, corresponding to fragments of
 natural mucopolysaccharides, and their biol. applications)
 RN 69892-44-0 HCAPLUS
 CN α -D-Glucopyranoside, methyl 2-(acetylamino)-2-deoxy-3-O-
 (phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 85193-92-6 HCAPLUS
 CN α -D-Glucopyranoside, methyl 2-(acetylamino)-2-deoxy-3,6-bis-O-
 (phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 87907-06-0 HCAPLUS

CN α -D-Glucopyranoside, phenylmethyl 2-deoxy-2-
[[[(phenylmethoxy)carbonyl]amino]-3-O-(phenylmethyl)-, 6-acetate (CA INDEX
NAME)


Absolute stereochemistry.



RN 87907-35-5 HCAPLUS

CN α -D-Glucopyranoside, methyl 2-deoxy-2-[[[(phenylmethoxy)carbonyl]amin
o]-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 87907-36-6 HCAPLUS

CN α -D-Glucopyranoside, methyl 2-deoxy-2-[[[(phenylmethoxy)carbonyl]amin
o]-3-O-(phenylmethyl)-, 6-benzoate (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
TI KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
AB The present invention provides, inter alia, peptides, peptide dimer, and
multimeric complexes comprising at least one binding moiety for KDR or
VEGF/KDR complex, which have a variety of uses wherever treating,
detecting, isolating or localizing angiogenesis is advantageous.
Particularly disclosed are synthetic, isolated polypeptides capable of
binding KDR or VEGF/KDR complex with high affinity (e.g., having a $KD < 1$
 μM), and dimer and multimeric constructs comprising these polypeptides.
AN 2005:1201059 HCAPLUS <<LOGINID::20080616>>
DN 143:483093
TI KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
IN Sato, Aaron K.; Sexton, Daniel J.; Dransfield, Daniel T.; Ladner, Robert
C.; Arbogast, Christophe; Bussat, Philippe; Fan, Hong; Khurana, Sudha;
Linder, Karen E.; Marinelli, Edmund R.; Nanjappan, Palaniappa; Nunn,
Adrian D.; Pillai, Radhakrishna; Pochon, Sibylle; Ramalingam,
Kondareddiar; Shrivastava, Ajay; Song, Bo; Swenson, Rolf E.; Von Wronski,
Mathew A.
PA USA
SO U.S. Pat. Appl. Publ., 436 pp., Cont.-in-part of U.S. Ser. No. 661,156.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 6

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----------------|--|----------|-----------------|--------------|
| US 20050250700 | A1 | 20051110 | US 2004-939890 | 20040913 <-- |
| WO 2003074005 | A2 | 20030912 | WO 2003-US6731 | 20030303 <-- |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| US 20050100963 | A1 | 20050512 | US 2003-661156 | 20030911 <-- |
| WO 2006031885 | A2 | 20060323 | WO 2005-US32740 | 20050913 |
| WO 2006031885 | A3 | 20060817 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, | | | |

NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2002-360851P P 20020301 <--
 US 2003-440411P P 20030115
 US 2003-382082 B2 20030303
 WO 2003-US6731 A2 20030303
 US 2003-661156 A2 20030911
 US 2004-939890 A 20040913


IT 599211-70-8P 599211-95-7P
 RL: DGN (Diagnostic use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy)



RN 599211-70-8 HCAPLUS

CN L-Lysinamide, N-acetyl-L-valyl-L-cysteinyl-L-tryptophyl-L- α -glutamyl-L- α -aspartyl-L-seryl-L-tryptophylglycylglycyl-L- α -glutamyl-L-valyl-L-cysteinyl-L-phenylalanyl-L-arginyl-L-tyrosyl-L- α -aspartyl-L-prolylglycylglycylglycyl-N6-[O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- α -D-galactopyranosyl]-L-serylglycyl-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- α -D-galactopyranosyl]-L-seryl]-, cyclic (2 \rightarrow 12)-disulfide (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






PAGE 1-D



PAGE 2-A

Ph

PAGE 2-B



PAGE 2-C




RN 599211-95-7 HCAPLUS
CN L-Lysinamide, N-acetyl-L-valyl-L-cysteinyl-L-tryptophyl-L- α -glutamyl-


L- α -aspartyl-L-seryl-L-tryptophylglycylglycyl-L- α -glutamyl-L-valyl-L-cysteinyl-L-phenylalanyl-L-arginyl-L-tyrosyl-L- α -aspartyl-L-prolylglycylglycylglycyl-N6-[N-[5-[(2,5-dioxo-1-pyrrolidinyl)oxy]-1,5-dioxopentyl]-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- α -D-galactopyranosyl]-L-serylglycyl-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- α -D-galactopyranosyl]-L-seryl]-, cyclic (2 \rightarrow 12)-disulfide (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C



PAGE 2-A

Ph


PAGE 2-B



PAGE 2-C



L13 ANSWER 3 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Tetrahydropyran compounds that interact with G protein-coupled receptors (GPCRs)
 GI



AB The invention discloses a method of inhibiting or effecting the activity of a GPCR which comprises contacting a GPCR with a compound I [Z = S, O, NRA (RA = R1-R5, C1-15 acyl, etc.); X = O, NRA; R1-R5 = H, C1-12 alkyl, C4-15 aryl, etc.; with provisos; ring may be of any configuration], or a pharmaceutically acceptable salt thereof. Libraries of compds. of the invention were tested for activity in assays using melanocortin and somatostatin receptors.

AN 2004:333585 HCAPLUS <<LOGINID:20080616>>
 DN 140:350624

TI Tetrahydropyran compounds that interact with G protein-coupled receptors (GPCRs)

IN Meutermans, Wim; Thanh, Giang Le; Abbenante, Giovanni; Tometzki, Gerald; Halliday, Judy; Zeugg, Johannes

PA Alchemia Pty. Ltd., Australia

SO PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|--------------|
| PI | WO 2004032940 | A1 | 20040422 | WO 2003-AU1347 | 20031010 <-- |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2499677 | A1 | 20040422 | CA 2003-2499677 | 20031010 <-- |
| | AU 2003266858 | A1 | 20040504 | AU 2003-266858 | 20031010 <-- |
| | AU 2003266858 | B2 | 20060914 | | |
| | EP 1549325 | A1 | 20050706 | EP 2003-747740 | 20031010 <-- |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | CN 1703228 | A | 20051130 | CN 2003-8010113 | 20031010 <-- |
| | JP 2006504718 | T | 20060209 | JP 2004-542106 | 20031010 <-- |
| | US 20060223764 | A1 | 20061005 | US 2003-530851 | 20031010 <-- |
| | IN 2005KN00858 | A | 20060609 | IN 2005-KN858 | 20050511 <-- |
| | IN 2007KN03028 | A | 20071130 | IN 2007-KN3028 | 20070817 <-- |

PRAI AU 2002-951995 A 20021011 <--
 WO 2003-AU1347 W 20031010
 IN 2005-KN858 A3 20050511

OS MARPAT 140:350624
 IT 681150-90-3
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (202tetrahydropyran compds. that interact with G protein-coupled
 receptors)

RN 681150-90-3 HCAPLUS
 CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-
 deoxy-3-O- (2-naphthalenylmethyl)-6-O- (phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



IT 681172-12-3 681172-78-1 681173-27-3
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (ktetrahydropyran compds. that interact with G protein-coupled
 receptors)


RN 681172-12-3 HCAPLUS
 CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-
 3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio-
 (CA INDEX NAME)

Absolute stereochemistry.



RN 681172-78-1 HCAPLUS
 CN D-Allopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-
 2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-27-3 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 681147-35-3 681147-36-4 681147-37-5
 681147-38-6 681147-39-7 681147-40-0
 681147-41-1 681147-42-2 681147-43-3
 681147-44-4 681147-45-5 681147-46-6
 681147-47-7 681147-48-8 681147-49-9
 681147-50-2 681147-51-3 681147-52-4
 681147-53-5 681147-54-6 681147-55-7
 681147-56-8 681147-57-9 681147-58-0
 681147-59-1 681147-60-4 681147-61-5
 681147-62-6 681147-63-7 681147-64-8
 681147-65-9 681147-66-0 681147-68-2
 681147-69-3 681147-70-6 681147-71-7
 681147-72-8 681147-73-9 681147-74-0
 681147-75-1 681147-76-2 681147-77-3
 681147-78-4 681147-79-5 681147-80-8
 681147-81-9 681147-82-0 681147-83-1
 681147-84-2 681147-85-3 681147-86-4
 681147-87-5 681147-88-6 681147-89-7
 681147-90-0 681147-91-1 681147-92-2
 681147-93-3 681147-94-4 681147-95-5
 681147-96-6 681147-97-7 681147-98-8

681147-99-9 681148-00-5 681148-01-6
681148-02-7 681148-03-8 681148-04-9
681148-05-0 681148-06-1 681148-07-2
681148-08-3 681148-09-4 681148-10-7
681148-11-8 681148-12-9 681148-13-0
681148-14-1 681148-15-2 681148-16-3
681148-17-4 681148-18-5 681148-19-6
681148-20-9 681148-21-0 681148-22-1
681148-23-2 681148-24-3 681148-25-4
681148-26-5 681148-27-6 681148-28-7
681148-29-8 681148-30-1 681148-31-2
681148-32-3 681148-33-4 681148-34-5
681148-35-6 681148-36-7 681148-37-8
681148-38-9 681148-39-0 681148-40-3
681148-41-4 681148-42-5 681148-43-6
681148-44-7 681148-45-8 681148-46-9
681148-47-0 681148-48-1 681148-49-2
681148-50-5 681148-51-6 681150-14-1
681150-16-3 681150-20-9 681150-22-1
681150-25-4 681150-27-6 681150-28-7
681150-31-2 681150-32-3 681150-33-4
681150-34-5 681150-39-0 681150-40-3
681150-41-4 681150-42-5 681150-43-6
681150-44-7 681150-45-8 681150-46-9
681150-47-0 681150-48-1 681150-49-2
681150-50-5 681150-51-6 681150-52-7
681150-53-8 681150-54-9 681150-55-0
681150-56-1 681150-57-2 681150-58-3
681150-59-4 681150-60-7 681150-61-8
681150-62-9 681150-63-0 681150-64-1
681150-65-2 681150-66-3 681150-67-4
681150-68-5 681150-69-6 681150-70-9
681150-71-0 681150-72-1 681150-73-2
681150-74-3 681150-75-4 681150-76-5
681150-77-6 681150-78-7 681150-79-8
681150-80-1 681150-81-2 681150-82-3
681150-83-4 681150-84-5 681150-85-6
681150-86-7 681150-87-8 681150-88-9
681150-89-0 681150-91-4 681150-92-5
681150-93-6 681150-94-7 681150-95-8
681150-96-9 681150-97-0 681150-98-1
681150-99-2 681151-00-8 681151-01-9
681151-02-0 681151-03-1 681151-04-2
681151-05-3 681151-06-4 681151-07-5
681151-08-6 681151-09-7 681151-10-0
681151-11-1 681151-12-2 681151-13-3
681151-14-4 681151-15-5 681151-16-6
681151-17-7 681151-18-8 681151-19-9
681151-20-2 681151-21-3 681151-22-4
681151-23-5 681151-24-6 681151-25-7
681151-26-8 681151-27-9 681151-28-0
681151-29-1 681151-31-5 681151-32-6
681151-33-7 681151-34-8 681151-35-9
681151-36-0 681151-37-1 681151-38-2
681151-39-3 681151-40-6 681151-41-7
681151-42-8 681151-43-9 681151-44-0
681151-45-1 681151-46-2 681151-47-3
681151-48-4 681151-49-5


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(tetrahydropyran compds. that interact with G protein-coupled

receptors)

RN 681147-35-3 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-
[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-
2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-36-4 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-
[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(2-
naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-37-5 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-38-6 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-39-7 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)aminolacetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-40-0 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-41-1 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-42-2 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-43-3 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-44-4 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-45-5 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-46-6 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[(4-[(aminoiminomethyl)amino]-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-47-7 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(1,1'-biphenyl)-4-ylmethyl]-2-deoxy-6-O-methyl-
(CA INDEX NAME)


Absolute stereochemistry.



RN 681147-48-8 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-49-9 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-50-2 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-51-3 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-52-4 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-53-5 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(1,1'-biphenyl)-4-ylmethyl]-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-54-6 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-55-7 HCAPLUS

CN D-Glucopyranoside, (3-hydroxyphenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-56-8 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-[(3-hydroxyphenyl)methyl]-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-57-9 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-[(3-hydroxyphenyl)methyl]-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-58-0 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-3-O-[(3-hydroxyphenyl)methyl]-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-59-1 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-[(3-hydroxyphenyl)methyl]-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-60-4 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-[(3-hydroxyphenyl)methyl]-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-61-5 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-[(3-hydroxyphenyl)methyl]-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-62-6 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-63-7 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[4-
[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-
ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-64-8 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[4-
[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(2-
naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-65-9 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-
[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-
(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-66-0 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-
[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-
2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-68-2 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-69-3 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[4-[(aminoininomethyl)amino]-1-oxobutyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-70-6 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-71-7 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-72-8 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-
([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-73-9 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-74-0 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-75-1 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-76-2 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-77-3 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-78-4 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-79-5 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-80-8 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-81-9 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[4-(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-82-0 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-83-1 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-84-2 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-85-3 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-86-4 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-87-5 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-88-6 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-89-7 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-90-0 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-
[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-
2-deoxy-3-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-91-1 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-
[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-([1,1'-biphenyl]-4-
ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-92-2 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-93-3 HCAPLUS


CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681147-94-4 HCAPLUS
 CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-
 [(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3-O-methyl-6-O-(2-
 naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 681147-95-5 HCAPLUS
 CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[(4-amino-1-
 oxobutyl)amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX
 NAME)


Absolute stereochemistry.



RN 681147-96-6 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-97-7 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-98-8 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681147-99-9 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-00-5 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-[[4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-01-6 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-02-7 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-03-8 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-04-9 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-05-0 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-06-1 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-07-2 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-08-3 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-09-4 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-10-7 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-11-8 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-12-9 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-13-0 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-[(1,1'-biphenyl)-4-ylmethyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-14-1 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-15-2 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-16-3 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-17-4 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acet-
 tylamino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



RN 681148-18-5 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-
 1-oxopropylamino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl-
 (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-19-6 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-20-9 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-[(aminoiminomethyl)amino]-1-oxobutyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-21-0 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-22-1 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-23-2 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-24-3 HCAPLUS


CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681148-25-4 HCAPLUS
 CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-methyl-6-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 681148-26-5 HCAPLUS
 CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-27-6 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-28-7 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-29-8 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-30-1 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[[4-[(aminoiminomethyl)amino]acetyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-31-2 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-32-3 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-33-4 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-34-5 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-35-6 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-36-7 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-37-8 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-38-9 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-39-0 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-40-3 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-41-4 HCAPLUS

CN D-Glucopyranoside, 2-phenylethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-42-5 HCAPLUS

CN D-Glucopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-6-O-[(3-hydroxyphenyl)methyl]-3-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-43-6 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-[(3-hydroxyphenyl)methyl]-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-44-7 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-[(3-hydroxyphenyl)methyl]-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-45-8 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-[(3-hydroxyphenyl)methyl]-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-46-9 HCAPLUS

CN D-Glucopyranoside, (3-hydroxyphenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 681148-47-0 HCAPLUS

CN D-Glucopyranoside, (3-hydroxyphenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-48-1 HCAPLUS

CN D-Glucopyranoside, (3-hydroxyphenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-49-2 HCAPLUS

CN D-Glucopyranoside, (3-hydroxyphenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-50-5 HCAPLUS

CN D-Glucopyranoside, (3-hydroxyphenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681148-51-6 HCAPLUS

CN D-Glucopyranoside, (3-hydroxyphenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-14-1 HCAPLUS

CN D-Glucopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-2-deoxy-2-[(1-oxo-3-phenylpropyl)amino]-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-16-3 HCAPLUS

CN D-Glucopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-2-deoxy-2-[(1H-indol-3-ylacetyl)amino]-6-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-20-9 HCAPLUS

CN D-Glucopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-2-[(phenylacetyl)amino]-1-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681150-22-1 HCAPLUS

CN D-Glucopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-6-O-[(4-

chlorophenyl)methyl]-2-deoxy-2-[(1H-indol-3-ylacetyl)amino]-1-thio- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 681150-25-4 HCAPLUS

CN D-Glucopyranoside, methyl 6-O-[(3-aminophenyl)methyl]-2-deoxy-2-[(phenylacetyl)amino]-3-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-27-6 HCAPLUS

CN D-Glucopyranoside, methyl 6-O-[(3-aminophenyl)methyl]-2-deoxy-2-[(1H-indol-3-ylacetyl)amino]-3-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681150-28-7 HCAPLUS

CN D-Glucopyranoside, methyl 6-O-[(3-aminophenyl)methyl]-2-deoxy-2-[(1H-

indol-3-yl)-1-oxopropyl]amino]-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)

Absolute stereochemistry.




RN 681150-31-2 HCAPLUS

CN D-Glucopyranoside, methyl 6-O-[(3-aminophenyl)methyl]-2-deoxy-2-[(1-oxo-3-phenyl-2-propen-1-yl)amino]-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 681150-32-3 HCAPLUS

CN D-Glucopyranoside, methyl 6-O-[(3-aminophenyl)methyl]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-2-[(phenylacetyl)amino]-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-33-4 HCAPLUS


CN D-Glucopyranoside, methyl 6-O-[(3-aminophenyl)methyl]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-2-[(1-oxo-3-phenyl-2-propen-1-yl)amino]-1-thio- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 681150-34-5 HCAPLUS
CN D-Glucopyranoside, methyl 6-O-[(3-aminophenyl)methyl]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-2-[(1H-indol-3-ylacetyl)amino]-1-thio- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 681150-39-0 HCAPLUS
CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-40-3 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-
[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-41-4 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3,6-
bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-42-5 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-43-6 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-44-7 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-45-8 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-46-9 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3,6-bis-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-47-0 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-48-1 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-49-2 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-50-5 HCAPLUS

D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-51-6 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-
[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX
NAME)


Absolute stereochemistry.



RN 681150-52-7 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-53-8 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3,6-bis-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-54-9 HCAPLUS

CN D-Glucopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-55-0 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-56-1 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-57-2 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-58-3 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-59-4 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-60-7 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-61-8 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3,6-bis-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-62-9 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-63-0 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-64-1 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-65-2 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-66-3 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-67-4 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-68-5 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-69-6 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-70-9 HCAPLUS

CN D-Glucopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-71-0 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-72-1 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-73-2 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-74-3 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-75-4 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-76-5 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-77-6 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-78-7 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3,6-bis-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 681150-79-8 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-6-O-[(4-

chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-80-1 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-81-2 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-82-3 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-83-4 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-84-5 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-85-6 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-86-7 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-87-8 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-
[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-88-9 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3,6-
bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-89-0 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-
deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-91-4 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-92-5 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-93-6 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3,6-bis-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-94-7 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-95-8 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-96-9 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-97-0 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-98-1 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681150-99-2 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-00-8 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-01-9 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-02-0 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-03-1 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-04-2 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-05-3 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-06-4 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-07-5 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-08-6 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-09-7 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-10-0 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-11-1 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-12-2 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-6-O-[(4-chlorophenyl)methyl]-2-deoxy-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-13-3 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-14-4 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-15-5 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-16-6 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-17-7 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-18-8 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-19-9 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-20-2 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-6-O-(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-21-3 HCAPLUS

CN D-Glucopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(2-phenylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-22-4 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-
[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-
deoxy-6-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-23-5 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-
[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-
deoxy-6-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-24-6 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-
[[[(aminoiminomethyl)amino]acetyl]amino]-3,6-bis-O-[(4-
chlorophenyl)methyl]-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681151-25-7 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-
[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3-O-(2-
naphthalenylmethyl)-6-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-
[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-
deoxy-3-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-
[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-
2-deoxy-6-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-28-0 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-
[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-
6-O-[(4-chlorophenyl)methyl]-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-29-1 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-
[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-
2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-31-5 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-32-6 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-
[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3,6-bis-O-[(4-
chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-33-7 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-
[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3,6-bis-O-(2-
naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-34-8 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-35-9 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-36-0 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-
[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-
ylmethyl)-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-37-1 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-
[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-
ylmethyl)-2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-38-2 HCAPLUS

CN D-Allopyranoside, [1,1'-biphenyl]-4-ylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-6-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-39-3 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-40-6 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 681151-41-7 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-42-8 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-43-9 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 681151-44-0 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-45-1 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(1,1'-biphenyl)-4-ylmethyl]-2-deoxy-6-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-46-2 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-47-3 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-6-O-[(4-chlorophenyl)methyl]-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-48-4 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-49-5 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)-(CA INDEX NAME)

Absolute stereochemistry.



IT 681151-50-8 681151-51-9 681151-52-0
 681151-53-1 681151-54-2 681151-55-3
 681151-56-4 681171-65-3 681171-66-4
 681171-67-5 681171-68-6 681171-69-7
 681171-70-0 681171-71-1 681171-72-2
 681171-73-3 681171-74-4 681171-75-5
 681171-76-6 681171-77-7 681171-78-8
 681171-79-9 681171-80-2 681171-81-3
 681171-82-4 681171-83-5 681171-84-6
 681171-85-7 681171-86-8 681171-87-9
 681171-88-0 681171-89-1 681171-90-4
 681171-91-5 681171-92-6 681171-93-7
 681171-94-8 681171-95-9 681171-96-0
 681171-97-1 681171-98-2 681171-99-3
 681172-00-9 681172-01-0 681172-02-1
 681172-03-2 681172-04-3 681172-05-4
 681172-06-5 681172-07-6 681172-08-7
 681172-09-8 681172-10-1 681172-11-2
 681172-13-4 681172-14-5 681172-15-6
 681172-16-7 681172-17-8 681172-18-9
 681172-19-0 681172-20-3 681172-21-4
 681172-22-5 681172-23-6 681172-24-7
 681172-25-8 681172-26-9 681172-27-0
 681172-28-1 681172-29-2 681172-30-5
 681172-31-6 681172-32-7 681172-33-8
 681172-34-9 681172-35-0 681172-36-1
 681172-37-2 681172-38-3 681172-39-4
 681172-40-7 681172-41-8 681172-42-9
 681172-43-0 681172-44-1 681172-45-2
 681172-46-3 681172-47-4 681172-48-5


681172-49-6 681172-50-9 681172-51-0
 681172-52-1 681172-53-2 681172-54-3
 681172-55-4 681172-56-5 681172-57-6
 681172-58-7 681172-59-8 681172-60-1
 681172-61-2 681172-62-3 681172-63-4
 681172-64-5 681172-65-6 681172-66-7
 681172-67-8 681172-68-9 681172-69-0
 681172-70-3 681172-71-4 681172-72-5
 681172-73-6 681172-74-7 681172-75-8
 681172-76-9 681172-77-0 681172-79-2
 681172-80-5 681172-81-6 681172-82-7
 681172-83-8 681172-84-9 681172-85-0
 681172-86-1 681172-88-3 681172-89-4
 681172-90-7 681172-91-8 681172-92-9
 681172-93-0 681172-94-1 681172-95-2
 681172-96-3 681172-97-4 681172-98-5
 681172-99-6 681173-00-2 681173-01-3
 681173-02-4 681173-03-5 681173-04-6
 681173-05-7 681173-06-8 681173-07-9
 681173-08-0 681173-09-1 681173-10-4
 681173-11-5 681173-12-6 681173-13-7
 681173-14-8 681173-15-9 681173-16-0
 681173-17-1 681173-18-2 681173-19-3
 681173-20-6 681173-21-7 681173-22-8
 681173-23-9 681173-24-0 681173-25-1
 681173-26-2 681173-28-4 681173-29-5
 681173-30-8 681173-31-9 681173-32-0
 681173-33-1 681173-34-2 681173-35-3
 681173-36-4 681173-37-5 681173-38-6
 681173-39-7 681173-40-0 681173-41-1
 681173-42-2 681173-43-3 681173-44-4
 681173-45-5 681173-46-6 681173-47-7
 681173-48-8 681173-49-9 681173-50-2
 681173-51-3 681173-52-4 681173-53-5
 681173-54-6 681173-55-7 681173-56-8
 681173-57-9 681173-58-0 681173-59-1
 681173-60-4 681173-61-5 681173-62-6
 681173-64-8 681173-66-0 681173-70-6
 681173-73-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (tetrahydropyran compds. that interact with G protein-coupled
 receptors)

RN 681151-50-8 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-
 oxopropyl]amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX
 NAME)


Absolute stereochemistry.



RN 681151-51-9 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-52-0 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-53-1 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-54-2 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(1,1'-biphenyl)-4-ylmethyl]-2-deoxy-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-55-3 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681151-56-4 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-6-O-[(4-chlorophenyl)methyl]-2-deoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-65-3 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-2-deoxy-3,6-bis-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-66-4 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3,6-bis-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-67-5 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3,6-bis-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-68-6 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3,6-bis-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-69-7 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3,6-bis-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-70-0 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-3,6-bis-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-71-1 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-72-2 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-73-3 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-74-4 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-75-5 HCAPLUS


CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)

Absolute stereochemistry.




RN 681171-76-6 HCAPLUS
 CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)

Absolute stereochemistry.




RN 681171-77-7 HCAPLUS
 CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 681171-78-8 HCAPLUS
 CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-79-9 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-80-2 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-81-3 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-82-4 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-((1,1'-biphenyl)-4-ylmethyl)-2-deoxy-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-83-5 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-84-6 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-85-7 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-86-8 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-87-9 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-88-0 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-(2-naphthalenylmethyl)-3-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-89-1 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-90-4 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-91-5 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-92-6 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-93-7 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-94-8 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-95-9 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-96-0 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3,6-bis-O-[4-chlorophenyl)methyl]-2-deoxy-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-97-1 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-3,6-bis-O-[4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-98-2 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3,6-bis-O-[4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681171-99-3 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-00-9 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3,6-bis-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)

Absolute stereochemistry.




RN 681172-01-0 HCAPLUS

CN D-Allopyranoside, methyl 2-(aminoacetyl)amino]-6-O-([1,1'-biphenyl]-4-

ylmethyl)-3-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-02-1 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-3-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-03-2 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-3-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-04-3 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-3-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-05-4 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-3-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-06-5 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-3-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-07-6 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-08-7 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-09-8 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-10-1 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-11-2 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-13-4 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-14-5 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-15-6 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-16-7 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-17-8 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-18-9 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-19-0 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-6-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-20-3 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-
 ([1,1'-biphenyl]-4-ylmethyl)-6-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-21-4 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-3-O-([1,1'-
 biphenyl]-4-ylmethyl)-6-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA
 INDEX NAME)


Absolute stereochemistry.



RN 681172-22-5 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-
 oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-6-O-[(4-
 chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-23-6 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-6-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-24-7 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-6-O-[(4-chlorophenyl)methyl]-2-deoxy-1-thio- (CA INDEX NAME)

Absolute stereochemistry.




RN 681172-25-8 HCAPLUS

CN D-Allopyranoside, methyl 2-(aminoacetyl)amino]-3,6-bis-O-([1,1'-biphenyl]-

4-ylmethyl)-2-deoxy-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-26-9 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3,6-bis-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-27-0 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-3,6-bis-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-28-1 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3,6-bis-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-29-2 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-3,6-bis-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-30-5 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3,6-bis-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-31-6 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-32-7 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-33-8 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-34-9 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-35-0 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-36-1 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-37-2 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-38-3 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-39-4 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-40-7 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-41-8 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-42-9 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-3-O-(2-naphthalenylmethyl)-6-O-(phenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-43-0 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-44-1 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 681172-45-2 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-46-3 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-47-4 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-48-5 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-[(4-chlorophenyl)methyl]-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-49-6 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-50-9 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-51-0 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)

Absolute stereochemistry.




RN 681172-52-1 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(2-

naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-53-2 HCAPLUS

CN D-Allopyranoside, methyl 2-[(4-amino-1-oxobutyl)amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-54-3 HCAPLUS

CN D-Allopyranoside, methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-6-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-3-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-55-4 HCAPLUS

CN D-Allopyranoside, methyl 2-[(aminoacetyl)amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-56-5 HCAPLUS

CN D-Allopyranoside, methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-57-6 HCAPLUS

CN D-Allopyranoside, methyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-58-7 HCAPLUS

CN D-Allopyranoside, methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-3,6-bis-O-(2-naphthalenylmethyl)-1-thio- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-59-8 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(aminoacetyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 681172-60-1 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-

2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-61-2 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-62-3 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-63-4 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-64-5 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-65-6 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(aminoacetyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-66-7 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-67-8 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-68-9 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-69-0 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-70-3 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-71-4 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(aminoacetyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-72-5 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-73-6 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-74-7 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-75-8 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-76-9 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-77-0 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(aminoacetyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-79-2 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-80-5 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-81-6 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-82-7 HCAPLUS

CN D-Allopyranoside, phenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-83-8 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-84-9 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-85-0 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-86-1 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-88-3 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-89-4 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(aminoacetyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-90-7 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-91-8 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-92-9 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-93-0 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 681172-94-1 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



RN 681172-95-2 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(aminoacetyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-96-3 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-97-4 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-98-5 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681172-99-6 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-00-2 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-01-3 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(aminoacetyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-02-4 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-03-5 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-04-6 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-05-7 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-06-8 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-07-9 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[(aminoacetyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-08-0 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-09-1 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-10-4 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-11-5 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-12-6 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-13-7 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[(aminoacetyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-14-8 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-15-9 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-16-0 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-17-1 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-18-2 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-19-3 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[(aminoacetyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-20-6 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-21-7 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-22-8 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-23-9 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-24-0 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[[4-(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-25-1 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[(aminoacetyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-26-2 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-28-4 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-29-5 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-30-8 HCAPLUS

CN D-Allopyranoside, 2-phenylethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-31-9 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(aminoacetyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-32-0 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-33-1 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-34-2 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-35-3 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-36-4 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-37-5 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(aminoacetyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-38-6 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-39-7 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-40-0 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-41-1 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-42-2 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-[(4-chlorophenyl)methyl]-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-43-3 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(aminoacetyl)amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-44-4 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-45-5 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-3-O-
 ([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-46-6 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-47-7 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-3-O-
([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-48-8 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-3-O-([1,1'-biphenyl]-4-ylmethyl)-2-deoxy-6-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-49-9 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(aminoacetyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-50-2 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[[(aminoimino)amino]amino]acetyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-51-3 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(3-amino-1-oxopropyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-52-4 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[3-[(aminoiminomethyl)amino]-1-oxopropyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-53-5 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[(4-amino-1-oxobutyl)amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-54-6 HCAPLUS

CN D-Allopyranoside, 2-naphthalenylmethyl 2-[[4-[(aminoiminomethyl)amino]-1-oxobutyl]amino]-2-deoxy-6-O-methyl-3-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-55-7 HCAPLUS

CN D-Allopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-2-deoxy-2-[(phenylacetyl)amino]-1-thio-, 6-benzeneacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-56-8 HCAPLUS

CN D-Allopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-2-deoxy-2-[(phenylacetyl)amino]-1-thio-, 6-(1H-indole-3-carboxylate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-57-9 HCAPLUS

CN D-Allopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-2-deoxy-2-[(phenylacetyl)amino]-1-thio-, 6-(1H-indole-3-acetate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-58-0 HCAPLUS

CN D-Allopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-2-deoxy-2-[(phenylacetyl)amino]-1-thio-, 6-(1H-indole-3-propanoate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-59-1 HCAPLUS

CN D-Allopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-2-[[[(4-chlorophenyl)acetyl]amino]-2-deoxy-1-thio-, 6-benzoate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-60-4 HCAPLUS

CN D-Allopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-2-[[[(4-chlorophenyl)acetyl]amino]-2-deoxy-1-thio-, 6-benzeneacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-61-5 HCAPLUS

CN D-Allopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-2-[[[(4-chlorophenyl)acetyl]amino]-2-deoxy-1-thio-, 6-(1H-indole-3-carboxylate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-62-6 HCAPLUS

CN D-Allopyranoside, methyl 3-O-[(3-aminophenyl)methyl]-2-[[[(4-chlorophenyl)acetyl]amino]-2-deoxy-1-thio-, 6-(1H-indole-3-acetate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-64-8 HCAPLUS

CN D-Allopyranoside, methyl 6-O-[(3-aminophenyl)methyl]-2-deoxy-2-[(phenylacetyl)amino]-3-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-66-0 HCAPLUS

CN D-Allopyranoside, methyl 6-O-[(3-aminophenyl)methyl]-2-deoxy-2-[(1H-indol-3-ylacetyl)amino]-3-O-(phenylmethyl)-1-thio- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-70-6 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-deoxy-2-[(2,3-diamino-1-oxopropyl)amino]-3-O-methyl-6-O-(2-naphthalenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681173-73-9 HCAPLUS

CN D-Allopyranoside, (4-chlorophenyl)methyl 2-[[[(aminoiminomethyl)amino]acetyl]amino]-2-deoxy-3-O-methyl-6-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN

TI KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

AB The present invention relates to polypeptides useful for detecting and

targeting primary receptors on endothelial cells for VEGF, i.e., VEGF receptor 2, also known as kinase domain region (KDR) and fetal liver kinase-1 (Flk-1), and for imaging and targeting complexes formed by VEGF and KDR. The involvement of VEGF and KDR in angiogenesis makes the VEGF/KDR and KDR binding polypeptides of the present invention particularly useful for imaging important sites of angiogenesis, e.g., neoplastic tumors, for targeting substances, e.g., therapeutics, including radiotherapeutics, to such sites, and for treating certain disease states, including those associated with inappropriate angiogenesis. Disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a $KD < 1 \mu M$).

AN 2003/719271 HCAPLUS <<LOGINID:20080616>>

DN 139:265740

TI KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

IN Sato, Aaron K.; Sexton, Daniel J.; Ladner, Robert C.; Dransfield, Daniel

T.; Swenson, Rolf E.; Marinelli, Edmund R.; Ramalingam, Kondareddi;

Nunn, Adrian D.; Von Wronski, Mathew A.; Shrivastava, Ajay; Pochon,

Sibylle; Bussat, Philippe; Arbogast, Christophe; Pillai, Radhakrishna;

Fan, Hong; Linder, Karen E.; Song, Bo; Nanjappan, Palaniappa

PA Dyax Corp., USA; Bracco International B.V.; et al.

SO PCT Int. Appl., 350 pp.

CODEN: P1XXD2

DT Patent

LA English


FAN.CNT 6



| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|----------------|--|----------|-----------------|--------------|
| PI | WO 2003074005 | A2 | 20030912 | WO 2003-US6731 | 20030303 <-- |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | CA 2477836 | A1 | 20030912 | CA 2003-2477836 | 20030303 <-- |
| | AU 2003213730 | A1 | 20030916 | AU 2003-213730 | 20030303 <-- |
| | EP 1572724 | A2 | 20050914 | EP 2003-711418 | 20030303 <-- |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| | JP 2006514915 | T | 20060518 | JP 2003-572527 | 20030303 <-- |
| | CA 2513044 | A1 | 20040805 | CA 2003-2513044 | 20030911 |
| | WO 2004065621 | A1 | 20040805 | WO 2003-US28787 | 20030911 <-- |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SZ, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | AU 2003278807 | A1 | 20040813 | AU 2003-278807 | 20030911 |
| | US 20050100963 | A1 | 20050512 | US 2003-661156 | 20030911 <-- |
| | EP 1587944 | A1 | 20051026 | EP 2003-770325 | 20030911 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |

| | | | | | |
|------|---|---------|----------|----------------|--------------|
| | US 20050250700 | A1 | 20051110 | US 2004-939890 | 20040913 <-- |
| | US 20080107607 | A1 | 20080508 | US 2006-608395 | 20061208 <-- |
| FRAI | US 2002-360851P | P | 20020301 | <-- | |
| | US 2003-440411P | P | 20030115 | | |
| | US 2003-382082 | A | 20030303 | | |
| | WO 2003-US6731 | W | 20030303 | | |
| | US 2003-661156 | A2 | 20030911 | | |
| | WO 2003-US28787 | W | 20030911 | | |
| | US 2005-749240P | P | 20051209 | | |
| | US 2006-833342P | P | 20060725 | | |
| OS | MARPAT 139:265740 | | | | |
| IT | 599211-70-8P 599211-95-7P | | | | |
| | RL: DGN (Diagnostic use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy) | | | | |
| RN | 599211-70-8 | HCAPLUS | | | |
| CN | L-Lysinamide, N-acetyl-L-valyl-L-cysteinyl-L-tryptophyl-L- α -glutamyl-L- α -aspartyl-L-seryl-L-tryptophylglycylglycyl-L- α -glutamyl-L-valyl-L-cysteinyl-L-phenylalanyl-L-arginyl-L-tyrosyl-L- α -aspartyl-L-prolylglycylglycylglycyl-N6-[O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- α -D-galactopyranosyl]-L-serylglycyl-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- α -D-galactopyranosyl]-L-seryl]-, cyclic (2 \rightarrow 12)-disulfide (CA INDEX NAME) | | | | |

Absolute stereochemistry.

PAGE 1-A






PAGE 1-D



PAGE 2-A

Ph

PAGE 2-B



PAGE 2-C




RN 599211-95-7 HCAPLUS
 CN L-Lysinamide, N-acetyl-L-valyl-L-cysteinyl-L-tryptophyl-L- α -glutamyl-


L- α -aspartyl-L-seryl-L-tryptophylglycylglycyl-L- α -glutamyl-L-valyl-L-cysteinyl-L-phenylalanyl-L-arginyl-L-tyrosyl-L- α -aspartyl-L-prolylglycylglycylglycyl-N6-[N-[5-[(2,5-dioxo-1-pyrrolidinyl)oxy]-1,5-dioxopentyl]-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- α -D-galactopyranosyl]-L-serylglycyl-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- α -D-galactopyranosyl]-L-seryl]-, cyclic (2 \rightarrow 12)-disulfide (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C



PAGE 2-A

Ph

PAGE 2-B




PAGE 2-C




L13 ANSWER 5 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Synthesis of monosulfated saccharides in the spacered form
 AB The sulfated (Su) saccharides 3-Su-Gal β , 3-Su-GalNAc β ,
 4-Su-GalNAc β , 6-Su-GalNAc α , 6-Su-GlcNAc β ,
 6-Su-LacNAc β , 6'-Su-LacNAc β , 3'-Su-Gal β 1-3GlcNAc β and
 3'-Su-Gal β 1-3GalNAc α , all monosaccharides in
 D-configuration, have been synthesized in the form of 3-aminopropyl or
 3-trifluoroacetamidopropyl glycosides.
 AN 2003:198768 HCAPLUS <<LOGINID::20080616>>
 DN 139:53232
 TI Synthesis of monosulfated saccharides in the spacered form
 AU Ovchinnikova, Tatyana V.; Shipova, Ekaterina V.; Sablina, Marina A.;
 Pazynina, Galina V.; Popova, Inna S.; Tuzikov, Aleksandr B.; Bovin,
 Nicolai V.
 CS M. M. Shemyakin-Yu. A. Ovchinnikov Institute of Bioorganic Chemistry,
 Russian Academy of Sciences, Moscow, 117997, Russia
 SO Mendeleev Communications (2002), (6), 213-215
 CODEN: MENCEX; ISSN: 0959-9436
 PB Russian Academy of Sciences
 DT Journal
 LA English
 OS CASREACT 139:53232
 IT 121042-74-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of monosulfated 3-aminopropyl or 3-trifluoroacetamidopropyl
 oligosaccharides)
 RN 121042-74-8 HCAPLUS
 CN Acetamide, N-[3-[[3-O-acetyl-2-(acetylamino)-2-deoxy-6-O-(phenylmethyl)-
 β -D-glucopyranosyl]oxy]propyl]-2,2,2-trifluoro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 546128-12-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of monosulfated 3-aminopropyl or 3-trifluoroacetamidopropyl
 oligosaccharides)
 RN 546128-12-5 HCAPLUS
 CN Acetamide, N-[3-[[3-O-acetyl-2-(acetylamino)-2-deoxy-6-O-(phenylmethyl)-
 β -D-galactopyranosyl]oxy]propyl]-2,2,2-trifluoro- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 6 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN

TI D-Glucose as a multivalent chiral scaffold for combinatorial chemistry
AB Due to their high d. of functional groups and their availability in a variety of diastereomeric forms, monosaccharides are considered attractive scaffolds for combinatorial chemical that allow the attachment and defined spatial alignment of up to five different pharmacophoric groups. For their application in combinatorial syntheses on solid phase, a set of selectively removable hydroxy protecting groups in combination with a cleavable anchor is required. Herein, we report on the construction and use of a versatile multivalent glucose building block for parallel synthesis on the solid phase.

AN 2002:862528 HCAPLUS <<LOGINID::20080616>>

DN 138:287884

TI D-Glucose as a multivalent chiral scaffold for combinatorial chemistry

AU Opatz, Till; Kallus, Christopher; Wunberg, Tobias; Schmidt, Wolfgang;

Henke, Stefan; Kunz, Horst

CS Institut für Organische Chemie, Universität Mainz, Mainz, 55128, Germany

SO Carbohydrate Research (2002), 337(21-23), 2089-2110

CODEN: CRBRAT; ISSN: 0008-6215

PB Elsevier Science Ltd.

DT Journal

LA English

OS CASREACT 138:287884

IT 505077-81-6P 505077-83-8P 505077-85-0P

505077-86-1P 505077-88-3P 505077-90-7P

505077-91-8P 505077-93-0P 505077-95-2P


RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)

(combinatorial preparation of alkylglycosides using D-glucose as a multivalent chiral synthon)

RN 505077-81-6 HCAPLUS


CN α -D-Glucopyranoside, butyl 2-O-butyl-3-O-propyl-, 6-[(2,4-difluorophenyl)carbamate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 505077-83-8 HCAPLUS
 CN α-D-Glucopyranoside, butyl 2-O-butyl-3-O-propyl-,
 6-[(3-cyanophenyl)carbamate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 505077-85-0 HCAPLUS
 CN α-D-Glucopyranoside, butyl 2-O-butyl-3-O-propyl-,
 6-[(4-methyl-3-nitrophenyl)carbamate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 505077-86-1 HCAPLUS
 CN α-D-Glucopyranoside, butyl 2-O-[(4-fluorophenyl)methyl]-3-O-propyl-,
 6-[(2,4-difluorophenyl)carbamate] (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 505077-88-3 HCAPLUS

CN α-D-Glucopyranoside, butyl 2-O-[(4-fluorophenyl)methyl]-3-O-propyl-,
6-[(3-cyanophenyl)carbamate] (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 505077-90-7 HCAPLUS

CN α-D-Glucopyranoside, butyl 2-O-[(4-fluorophenyl)methyl]-3-O-propyl-,
6-[(4-methyl-3-nitrophenyl)carbamate] (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 505077-91-8 HCAPLUS

CN α -D-Glucopyranoside, butyl 2-O-[(2-methylphenyl)methyl]-3-O-propyl-, 6-[(2,4-difluorophenyl)carbamate] (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 505077-93-0 HCAPLUS

CN α -D-Glucopyranoside, butyl 2-O-[(2-methylphenyl)methyl]-3-O-propyl-, 6-[(3-cyanophenyl)carbamate] (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 505077-95-2 HCAPLUS

CN α -D-Glucopyranoside, butyl 2-O-[(2-methylphenyl)methyl]-3-O-propyl-,
6-[(4-methyl-3-nitrophenyl)carbamate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Synthesis of tools for raising antibodies against moenomycin epitopes and
initial immunological studies

AB The moenomycins A and C1 as well as penta-, di- and monosaccharide
analogs have been conjugated to BSA and biotin, resp. The moenomycin
A-BSA conjugates have been used to raise polyclonal antibodies. It has
been demonstrated that the antisera recognize moenomycin A.

AN 2002:675350 HCAPLUS <<LOGINID:20080616>>

DN 137:351070

TI Synthesis of tools for raising antibodies against moenomycin epitopes and
initial immunological studies

AU Buchynskyy, Andrii; Stembera, Katherina; Knoll, Dietmar; Vogel, Stefan;
Kempin, Uwe; Biallass, Astrid; Hennig, Lothar; Findeisen, Matthias;
Muller, Dietrich; Welzel, Peter

CS Institut fur Organische Chemie, Fakultat fur Chemie und Mineralogie,
Universitat Leipzig, Leipzig, D-04103, Germany

SO Tetrahedron (2002), 58(38), 7741-7760

CODEN: TETRAB; ISSN: 0040-4020

PB Elsevier Science Ltd.

DT Journal

LA English

IT 201666-58-2 303185-58-2 350582-97-7

474903-27-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation and reaction of moenomycin analogs for biosynthesis of
antibodies against moenomycin epitopes)


RN 201666-58-2 HCAPLUS

CN α -D-Glucopyranuronamide, O-(5R)-5-C-[3-(3-carboxy-1-oxopropyl)-1-[3-
[(2-mercaptoethyl)amino]carbonyl]-4-nitrophenyl]-1H-1,2,4-triazol-5-yl]-
 α -L-arabinopyranosyl-(1 \rightarrow 4)-O-2-(acetyl amino)-2,6-dideoxy-
 β -D-glucopyranosyl-(1 \rightarrow 4)-O-[β -D-glucopyranosyl-
(1 \rightarrow 6)]-O-2-(acetyl amino)-2-deoxy- β -D-glucopyranosyl-


(1→2)-4-C-methyl-, 3-carbamate 1-[(2R)-2-carboxy-2-[(2Z,6E,13E)-3,8,8,14,18-pentamethyl-11-methylene-2,6,13,17-nonadecatetraenyl]oxy]ethyl hydrogen phosphate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




≡CMe₂



RN 303185-58-2 HCAPLUS
 CN α-D-Glucopyranuronamide, O-β-D-galactopyranuronamidoyl-
 (1→4)-O-2-(acetylamino)-2,6-dideoxy-β-D-glucopyranosyl-
 (1→4)-O-[β-D-glucopyranosyl-(1→6)]-O-2-(acetylamino)-2-
 deoxy-β-D-glucopyranosyl-(1→2)-4-C-methyl-, 3-carbamate
 1-[(2R)-2-carboxy-2-(2-oxoethoxy)ethyl hydrogen phosphate] (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.





OH

OH




RN 350582-97-7 HCAPLUS
 CN α -D-Glucopyranuronamide, O- β -D-galactopyranuronamidoyl-
 (1 \rightarrow 4)-O-2-(acetylamino)-2,6-dideoxy- β -D-glucopyranosyl-
 (1 \rightarrow 4)-O-[β -D-glucopyranosyl-(1 \rightarrow 6)]-O-2-(acetylamino)-2-
 deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-4-C-methyl-, 3-carbamate
 1-[(2R)-2-carboxy-2-[2-(methylamino)ethoxy]ethyl hydrogen phosphate] (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 474903-27-0 HCAPLUS
 CN α -D-Glucopyranuronamide, O-(5R)-5-C-[3-(3-carboxy-1-oxopropyl)-1-[3-[[[2-[(2-ethoxy-3,4-dioxo-1-cyclobuten-1-yl)amino]ethyl]amino]carbonyl]-4-nitrophenyl]-1H-1,2,4-triazol-5-yl]- α -L-arabinopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2,6-dideoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-O-[β -D-glucopyranosyl-(1 \rightarrow 6)]-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-4-C-methyl-, 3-carbamate 1-[(2R)-2-carboxy-2-[[[2Z,6E,13E]-3,8,14,18-pentamethyl-11-methylene-2,6,13,17-nonadecatetraenyl]oxy]ethyl hydrogen phosphate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.








IT 261640-46-4P 474903-26-9DP, albumin conjugates
 474903-28-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction of moenomycin analogs for biosynthesis of
 antibodies against moenomycin epitopes)

RN 261640-46-4 HCAPLUS
 CN α-D-Glucopyranuronamide, O-(5R)-5-C-[1-[3-[[[(2-
 aminoethyl)amino]carbonyl]-4-nitrophenyl]-3-(3-carboxy-1-oxopropyl)-1H-
 1,2,4-triazol-5-yl]-α-L-arabinopyranosyl-(1→4)-O-2-
 (acetylamino)-2,6-dideoxy-β-D-glucopyranosyl-(1→4)-O-[β-D-
 glucopyranosyl-(1→6)]-O-2-(acetylamino)-2-deoxy-β-D-
 glucopyranosyl-(1→2)-4-C-methyl-, 3-carbamate 1-[(2R)-2-carboxy-2-
 [[(2Z,6E,13E)-3,8,8,14,18-pentamethyl-11-methylene-2,6,13,17-
 nonadecatetraenyl]oxy]ethyl hydrogen phosphate] (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



 CMe₂






RN 474903-26-9 HCAPLUS

CN α-D-Glucopyranuronamide, O-(5R)-5-C-[1-[3-[[[2-[[1-(2-carboxyethyl)-2,5-dioxo-3-pyrrolidinyl]thio]ethyl]amino]carbonyl]-4-nitrophenyl]-3-(3-carboxy-1-oxopropyl)-1H-1,2,4-triazol-5-yl]-α-L-arabinopyranosyl-(1→4)-O-2-(acetylamino)-2,6-dideoxy-β-D-glucopyranosyl-(1→4)-O-[β-D-glucopyranosyl-(1→6)]-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-4-C-methyl-, 3-carbamate 1-[(2R)-2-carboxy-2-[[[(2Z,6E,13E)-3,8,8,14,18-pentamethyl-11-methylene-2,6,13,17-nonadecatetraenyl]oxy]ethyl hydrogen phosphate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Double bond geometry as shown.






RN 474903-28-1 HCAPLUS
 CN Propanoic acid, 2-[2-[(2-ethoxy-3,4-dioxo-1-cyclobuten-1-yl)methylamino]ethoxy]-3-[[[O-β-D-galactopyranuronamidosyl-(1→4)-O-2-(acetylamino)-2,6-dideoxy-β-D-glucopyranosyl-(1→4)-O-β-D-glucopyranosyl-(1→6)]-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-3-O-(aminocarbonyl)-4-C-methyl-α-D-glucopyranuronamidosyl]oxy]hydroxyphosphinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.






IT 474903-27-0DP, albumin conjugates 474903-28-1DP, albumin
 conjugates 474903-60-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and reaction of moenomycin analogs for biosynthesis of
 antibodies against moenomycin epitopes)
 RN 474903-27-0 HCAPLUS
 CN α -D-Glucopyranuronamide, O-(5R)-5-C-[3-(3-carboxy-1-oxopropyl)-1-[3-
 [[2-[(2-ethoxy-3,4-dioxo-1-cyclobuten-1-yl)amino]ethyl]amino]carbonyl]-4-
 nitrophenyl]-1H-1,2,4-triazol-5-yl]- α -L-arabinopyranosyl-
 (1 \rightarrow 4)-O-2-(acetyl amino)-2,6-dideoxy- β -D-glucopyranosyl-
 (1 \rightarrow 4)-O-[β -D-glucopyranosyl-(1 \rightarrow 6)]-O-2-(acetyl amino)-2-
 deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-4-C-methyl-, 3-carbamate
 1-[(2R)-2-carboxy-2-[[[(2Z,6E,13E)-3,8,8,14,18-pentamethyl-11-methylene-
 2,6,13,17-nonadecatetraenyl]oxy]ethyl hydrogen phosphate] (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




PAGE 1-B



PAGE 1-C



PAGE 2-A




RN 474903-28-1 HCAPLUS


CN Propanoic acid, 2-[2-[(2-ethoxy-3,4-dioxo-1-cyclobuten-1-yl)methylamino]ethoxy]-3-[[[10-β-D-galactopyranuronamidosyl-(1→4)-O-2-(acetylamino)-2,6-dideoxy-β-D-glucopyranosyl-(1→4)-O-[β-D-glucopyranosyl-(1→6)]-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-3-O-(aminocarbonyl)-4-C-methyl-α-D-glucopyranuronamidosyl]oxy]hydroxyphosphinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




PAGE 1-B






RN 474903-60-1 HCAPLUS
 CN 3,10,13,16-Tetraoxa-6,20-diazapentacosanoic acid, 2-[[[[[O-β-D-galactopyranuronamidoyl-(1→4)-O-2-(acetylamino)-2,6-dideoxy-β-D-glucopyranosyl-(1→4)-O-[β-D-glucopyranosyl-(1→6)]-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-3-O-(aminocarbonyl)-4-C-methyl-α-D-glucopyranuronamidoyl]oxy]hydroxyphosphinyl]oxy]methyl]-25-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-21-oxo-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.







IT 76095-39-1DP, Moenomycin A, albumin conjugates
 162895-32-1P, Moenomycin A12
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (synthesis of tools for raising antibodies against moenomycin epitopes
 and initial immunol. studies)
 RN 76095-39-1 HCAPLUS
 CN α -D-Glucopyranuronamide, O-[N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)-
 β -D-galactopyranuronamidoyl]-(1 \rightarrow 4)-O-2-(acetylamino)-2,6-
 dideoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-O-[β -D-glucopyranosyl-
 (1 \rightarrow 6)]-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-
 (1 \rightarrow 2)-4-C-methyl-, 3-carbamate 1-[(2R)-2-carboxy-2-[(2Z,6E,13E)-
 3,8,8,14,18-pentamethyl-11-methylene-2,6,13,17-nonadecatetraen-1-
 yl]oxy]ethyl hydrogen phosphate] (CA INDEX NAME)



Absolute stereochemistry.
 Double bond geometry as shown.






RN 162895-32-1 HCAPLUS
 CN α -D-Galactopyranuronamide, O- β -D-glucopyranosyl-(1 \rightarrow 6)-O-
 [O-[N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)- β -D-
 galactopyranuronamidosyl]-(1 \rightarrow 4)-2-(acetylamino)-2,6-dideoxy- β -
 D-glucopyranosyl-(1 \rightarrow 4)]-O-2-(acetylamino)-2-deoxy- β -D-
 glucopyranosyl-(1 \rightarrow 2)-, 3-carbamate 1-[(2R)-2-carboxy-2-
 [[[(2Z,6E,13E)-3,8,8,14,18-pentamethyl-11-methylene-2,6,13,17-
 nonadecatetraenyl]oxy]ethyl hydrogen phosphate] (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.






RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Combinatorial libraries of glucosamine monosaccharides
GI



I



II

AB The present invention provides a combinatorial synthesis of glucosamine monosaccharide I in which the monosaccharide ring is of the glucosamine or galactosamine configuration; R4 and R5 are hydrogen or together form an optionally substituted benzylidene acetal in which the optional substituent is chosen from halo, azido, alkoxy, nitro or alkyl; R3 is hydrogen; optionally substituted glycolate or optionally substituted lactate or derivs. thereof; or a carboxylic acid mimetic; R1 is optionally substituted acyl, optionally substituted benzoyl, optionally substituted biphenylcarbonyl, heteroaryl acyl, optionally substituted bicycloacyl, optionally substituted bicycloheteroacyl, sulfonamide, urea or carbamates; R2 is hydrogen; R1 and R2 together form succinimide, maleimide or optionally substituted phthalimide; R is N3, alkoxy, arylalkoxy, amine.

The invention also provides processes for the preparation of the compound of formula I and methods of screening for antibacterial or antibiotic compds. involving the compound of formula I. Thus, glucosamine II was prepared as potential antibacterial or antibiotic compound

2002:314953 HCAPLUS <<LOGINID:20080616>>

AN 136:325779

DN Combinatorial libraries of glucosamine monosaccharides

IN West, Michaelleo; Meutermans, Wim; Adamson, George; Schafer, Karl;

Schliebs, Darren

PA Alchemia Pty. Ltd., Australia

SO PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|--------------|
| PI | WO 2002032915 | A1 | 20020425 | WO 2001-AU1307 | 20011017 <-- |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2001095282 | A | 20020429 | AU 2001-95282 | 20011017 <-- |
| | EP 1326873 | A1 | 20030716 | EP 2001-975871 | 20011017 <-- |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | AU 2001295282 | B2 | 20061102 | AU 2001-295282 | 20011017 <-- |
| | US 20030232766 | A1 | 20031218 | US 2003-419070 | 20030417 <-- |
| PRAI | AU 2000-797 | A | 20001017 | <-- | |
| | AU 2001-95282 | A | 20011017 | <-- | |
| | WO 2001-AU1307 | W | 20011017 | <-- | |

OS MARPAT 136:325779

IT 412039-08-8P 412039-11-3P

RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)


(combinatorial libraries of glucosamine monosaccharides)

RN 412039-08-8 HCAPLUS

CN β -Normuramic acid, N-acetyl-1-O-(2-naphthalenylmethyl)- (9CI) (CA


INDEX NAME)

Absolute stereochemistry.



RN 412039-11-3 HCAPLUS
 CN β -Normuramic acid, N-(2,2-dimethyl-1-oxopropyl)-1-O-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L13 ANSWER 9 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI "Meshed-Bag Gathered-Bunch" Method for Solid-Phase Synthesis of Small Molecular Diverse Compounds
 AB A new "Meshed-Bag Gathered-Bunch" technol. for the solid-phase synthesis of peptide libraries was developed. Using this technol., the authors synthesized muramyl dipeptide mimetics including derivs. at the N- and C-terminus, cyclic muramyl dipeptide mimetics and muramyl dipeptide conjugates of tuftsin analogs. The advantages of this method include ease of manufacture, low unit cost of production, the phys. encoding method, and the compatibility with both parallel and "split-mix" approaches.
 AN 2002:73484 HCAPLUS <<LOGINID::20080616>>
 DN 136:263456
 TI "Meshed-Bag Gathered-Bunch" Method for Solid-Phase Synthesis of Small Molecular Diverse Compounds
 AU Zhang, Suo-De; Liu, Gang; Xia, Shu-Quan; Wu, Ping; Zhang, Liang
 CS Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, Peop. Rep. China
 SO Journal of Combinatorial Chemistry (2002), 4(2), 131-137
 CODEN: JCCHFF; ISSN: 1520-4766
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 136:263456
 IT 405313-66-8P 405313-67-9P 405313-70-4P
 405313-71-5P 405313-72-6P 405313-73-7P
 405313-74-8P 405313-75-9P 405313-76-0P
 405313-77-1P 405313-78-2P 405313-79-3P
 405313-80-6P 405313-81-7P 405313-82-8P
 405313-83-9P 405313-84-0P 405313-85-1P
 RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
 ("meshed-bag gathered-bunch" method-based solid-phase combinatorial synthesis of tuftsin peptide analogs, muramyl dipeptides and cyclic muramyl dipeptide mimetics)
 RN 405313-66-8 HCAPLUS
 CN L-Lysine, N-[N-acetyl-1-O-(phenylmethyl)- α -muramoyl]-L-alanyl-D- α -glutamyl-L-threonyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 405313-67-9 HCAPLUS


CN L-Lysine, N-[N-acetyl-1-O-(phenylmethyl)-α-muramoyl]-L-alanyl-D-α-glutaminy-L-lysyl-L-threonyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 405313-70-4 HCAPLUS

CN L-Lysine, N-[N-acetyl-1-O-(phenylmethyl)-α-muramoyl]-L-threonyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—NH₂

RN 405313-71-5 HCAPLUS


CN L-Lysine, N2-[N-acetyl-1-O-(phenylmethyl)- α -muramoyl]-L-lysyl-L-threonyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 405313-72-6 HCAPLUS

CN L-Lysine, N-[N-acetyl-1-O-(phenylmethyl)- α -muramoyl]-L-threonyl-D- α -glutamyl-L-threonyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 405313-73-7 HCAPLUS

CN L-Lysine, N-[N-acetyl-1-O-(phenylmethyl)-α-muramoyl]-L-threonyl-D-α-glutaminy-L-lysyl-L-threonyl-L-arginyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 405313-74-8 HCAPLUS

CN L-Lysine, N-[N-acetyl-1-O-(phenylmethyl)-α-muramoyl]-L-alanyl-D-α-glutaminy-L-threonyl-L-arginyl-L-prolyl-, 2-(phenylmethyl) ester

Absolute stereochemistry.

The chemical structure shows a substituted furanose ring on the left, with a phenyl group (Ph) attached via an oxygen atom. The ring has hydroxyl groups (OH) at the 2' and 3' positions and an NHAc group at the 4' position. The 5' carbon of the furanose is linked to an amide chain. This chain consists of several amide bonds, including a thioamide group (C=S) with a methyl group (Me) and a hydroxyl group (OH). The chain terminates in a thioamide group (C=S) with a methyl group (Me) and a hydroxyl group (OH). The structure is highly complex, with multiple stereocenters and functional groups.

PAGE 1-B





```

RN      405313-75-9      HCAPLUS
CN      L-lysine, N-[N-acetyl-1-O-(phenylmethyl)- $\alpha$ -muramoyl]-D- $\alpha$ -
        glutamyl-L-lysyl-L-threonyl-L-arginyl-L-prolyl-, 1-(phenylmethyl) ester
        (9CI) (CA INDEX NAME)

```


Absolute stereochemistry.



RN 405313-76-0 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)- α -muramoyl]-L-alanyl-D- α -glutamyl-N6-glycyl-, (2 \rightarrow 1')-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 405313-77-1 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)- α -muramoyl]-L-alanyl-D- α -glutamyl-N6- β -alanyl-, (2 \rightarrow 1')-lactam (9CI) (CA INDEX

NAME)


Absolute stereochemistry.



RN 405313-78-2 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)-α-muramoyl]-L-alanyl-D-α-glutamyl-N6-(4-amino-1-oxobutyl)-, (2→3)-lactam (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 405313-79-3 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)-α-muramoyl]-L-alanyl-D-α-glutamyl-N6-L-alanyl-, (2→1')-lactam (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 405313-80-6 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)-α-muramoyl]-L-alanyl-D-α-glutamyl-N6-D-alanyl-, (2→1')-lactam (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 405313-81-7 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)-α-muramoyl]-L-alanyl-D-α-glutamyl-N6-(L-alanyl-D-α-glutamyl)-, (2→1')-lactam (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 405313-82-8 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)- α -muramoyl]-L-alanyl-D- α -glutamyl-N6-(D-alanyl-D- α -glutamyl)-, (2+1')-lactam (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 405313-83-9 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)- α -muramoyl]-L-alanyl-D- α -glutamyl-N6-(L-alanyl-D- α -glutamyl)-, 2'-(phenylmethyl) ester, (2+1')-lactam (9CI) (CA INDEX NAME)

PAGE 1-A






RN 405313-84-0 HCAPLUS



CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)-α-muramoyl]-L-alanyl-D-α-glutamyl-N6-(L-alanyl-L-α-glutamyl)-, (2→1')-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 405313-85-1 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)-α-muramoyl]-L-alanyl-D-α-glutamyl-N6-(D-alanyl-L-glutamyl)-, (2→1')-lactam (9CI) (CA INDEX NAME)



IT 15892-26-9


RL: CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); RACT (Reactant or reagent)

("meshed-bag gathered-bunch" method-based solid-phase combinatorial synthesis of tuftsin peptide analogs, muramyl dipeptides and cyclic muramyl dipeptide mimetics)

RN 15892-26-9 HCAPLUS

CN α-Muramic acid, N-acetyl-1-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L13 ANSWER 10 OF 160 HCAPLUS COPYRIGHT 2008 ACS on STN
TI New efficient route for synthesis of lipid A by using affinity separation
AB New efficient synthesis of lipid A, an immunostimulating glycoconjugate of bacteria, was achieved for the construction of lipid A library by using synthesis based on affinity separation (SAS), where the compds. possessing a barbituric acid (BA)-tag are selectively and rapidly purified by interaction with an artificial receptor for BA. Glycosylation of a glycosyl acceptor possessing the BA-tag with a 4'-phosphorylated N-Troc glucosaminyl trichloroacetimidate gave the disaccharide 4'-phosphate, which was purified by the affinity separation. Successive removal of protective groups and introduction of acyl groups were then effected and the synthetic intermediate at each step was purified by the affinity separation. Cleavage of the tag and subsequent deprotection afforded Escherichia coli lipid A. SAS enabled the rapid preparation of lipid A, therefore, proved to be a promising method for synthesis of other complex glycoconjugates.
AN 2001:829976 HCAPLUS <<LOGINID:20080616>>
DN 136:200388
TI New efficient route for synthesis of lipid A by using affinity separation
AU Fukase, Yoshiyuki; Zhang, San-Qi; Iseki, Keiko; Oikawa, Masato; Fukase, Koichi; Kusumoto, Shoichi
CS Department of Chemistry, Graduate School of Science, Osaka University, Osaka, 560-0043, Japan
SO Synlett (2001), (11), 1693-1698
CODEN: SYNLES; ISSN: 0936-5214
PB Georg Thieme Verlag
DT Journal
LA English
OS CASREACT 136:200388
IT 400843-73-4P 400843-82-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of Escherichia coli glycolipid A via glycosidation by using affinity separation)
RN 400843-73-4 HCAPLUS
CN α -D-Glucopyranoside, 2-propen-1-yl 2-deoxy-4-O-[[4-[[5-[[3-[[4-[[5-ethylhexahydro-2,4,6-trioxo-5-pyrimidinyl)methyl]phenyl]methoxy]-3-oxopropyl]amino]-1,5-dioxopentyl]amino]phenyl]methyl]-2-[[[9H-fluoren-9-ylmethoxy)carbonyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 400843-82-5 HCAPLUS
 CN α -D-Glucopyranoside, (1E)-1-propenyl 2-deoxy-6-O-(phenylmethyl)-2-
 [[[(2,2,2-trichloroethoxy)carbonyl]amino]-, 3-(2-propenyl carbonate) (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 09:07:06 ON 16 JUN 2008)

FILE 'REGISTRY' ENTERED AT 09:07:15 ON 16 JUN 2008

L1 STRUCTURE UPLOADED
 L2 50 S L1
 L3 76450 S L1 SSS FULL
 L4 STRUCTURE UPLOADED
 L5 STRUCTURE UPLOADED

L6 STRUCTURE UPLOADED
L7 42345 S L4 SUB=L3 FULL
L8 9767 S L5 SUB=L7 FULL
L9 3925 S L6 SUB=L8 FULL

FILE 'CAPLUS' ENTERED AT 09:17:01 ON 16 JUN 2008
L10 1698 S L9

FILE 'STNGUIDE' ENTERED AT 09:17:10 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:18:05 ON 16 JUN 2008
L11 122010 S MONOSACCH? OR (BUILDING BLOCK) OR (LIBRARY)
L12 196 S L10 AND L11
L13 160 S L12 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'STNGUIDE' ENTERED AT 09:18:11 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:19:08 ON 16 JUN 2008

FILE 'STNGUIDE' ENTERED AT 09:19:09 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:19:31 ON 16 JUN 2008

FILE 'STNGUIDE' ENTERED AT 09:20:03 ON 16 JUN 2008

=> log hold

| | | |
|--|------------|---------|
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 0.06 | 376.86 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| CA SUBSCRIBER PRICE | 0.00 | -8.00 |

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 09:20:42 ON 16 JUN 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAEXO1623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'STNGUIDE' AT 09:21:46 ON 16 JUN 2008
FILE 'STNGUIDE' ENTERED AT 09:21:46 ON 16 JUN 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

| | | |
|--|------------|---------|
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 0.06 | 376.86 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| CA SUBSCRIBER PRICE | 0.00 | -8.00 |

=>

| | | |
|--|------------|---------|
| => file registry | | |
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 0.12 | 376.92 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| CA SUBSCRIBER PRICE | 0.00 | -8.00 |

FILE 'REGISTRY' ENTERED AT 09:22:10 ON 16 JUN 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 15 JUN 2008 HIGHEST RN 1028329-25-0
 DICTIONARY FILE UPDATES: 15 JUN 2008 HIGHEST RN 1028329-25-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
 Uploading C:\Documents and Settings\eolson\My Documents\e-Red
 Folder\10524048\10524048mainnot.str

L14 STRUCTURE UPLOADED

=> d his

(FILE 'HOME' ENTERED AT 09:07:06 ON 16 JUN 2008)

FILE 'REGISTRY' ENTERED AT 09:07:15 ON 16 JUN 2008

```

L1      STRUCTURE UPLOADED
L2      50 S L1
L3      76450 S L1 SSS FULL
L4      STRUCTURE UPLOADED
L5      STRUCTURE UPLOADED
L6      STRUCTURE UPLOADED
L7      42345 S L4 SUB=L3 FULL
L8      9767 S L5 SUB=L7 FULL
L9      3925 S L6 SUB=L8 FULL

```

L10 FILE 'CAPLUS' ENTERED AT 09:17:01 ON 16 JUN 2008
 1698 S L9

FILE 'STNGUIDE' ENTERED AT 09:17:10 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:18:05 ON 16 JUN 2008

L11 122010 S MONOSACCH? OR (BUILDING BLOCK) OR (LIBRARY)
L12 196 S L10 AND L11
L13 160 S L12 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'STNGUIDE' ENTERED AT 09:18:11 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:19:08 ON 16 JUN 2008

FILE 'STNGUIDE' ENTERED AT 09:19:09 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:19:31 ON 16 JUN 2008

FILE 'STNGUIDE' ENTERED AT 09:20:03 ON 16 JUN 2008

FILE 'REGISTRY' ENTERED AT 09:22:10 ON 16 JUN 2008

L14 STRUCTURE UPLOADED

=> s l14 sub=19

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full

FULL SUBSET SEARCH INITIATED 09:22:45 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 657 TO ITERATE

100.0% PROCESSED 657 ITERATIONS

337 ANSWERS

SEARCH TIME: 00.00.01

L15 337 SEA SUB=L9 SSS FUL L14

=> s l9 not l15

L16 3588 L9 NOT L15

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

43.02

419.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-8.00

FILE 'HCAPLUS' ENTERED AT 09:23:09 ON 16 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jun 2008 VOL 148 ISS 25

FILE LAST UPDATED: 15 Jun 2008 (20080615/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate

substance identification.

=> s l16

L17 1520 L16

=> s l17 and l13

L18 142 L17 AND L13

=> file stnguide

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

2.69 422.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL

ENTRY SESSION

CA SUBSCRIBER PRICE

0.00 -8.00

FILE 'STNGUIDE' ENTERED AT 09:23:32 ON 16 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jun 13, 2008 (20080613/UP).


=> d l18 20 ti abs bib hitetr

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L18 ANSWER 20 OF 142 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Combinatorial solid-phase synthesis of multivalent cyclic neoglycopeptides

GI



AB The authors have synthesized an 18-member library of carbohydrate-substituted cyclic peptides of the type cyclo[Boc-Lys-Pro-Lys(R)-Ala-Pro-Gly-Leu-Glu]-Bal-NH₂ [BOC = (CH₃)₃CO-C(=O); Bal = β-alanine; R = 2-acetyl-amino-2-deoxy-3,4,6-tri-O-acetyl-β-D-glucopyranosyl, which was connected via a -(Z)-CH₂CH:CHCH₂OC(O)- linker to side-chain amino groups of the cyclic peptide]. Using split-mix bead solid-phase synthesis techniques, up to three R groups were introduced to the cyclic peptide to test for directed multivalent activity in lectin binding. The urethane-type linker for sugar attachment gave virtually quant. yield, and allowed cleavage of the sugars from the cyclic peptide scaffold to allow for automated microsequencing of the scaffold under standard conditions. Using H₂C:CHCH₂OC(O), OCH₂CH:CH₂, and Ddv (I) as protecting groups for, resp., the N-terminal Lys, the C-terminal Glu side-chain, and

the side-chain amino groups to be sugar-substituted, the synthesis allowed on-head cyclization and side-chain substitution using selective deprotection reactions.



AN 2000:894358 HCAPLUS <<LOGINID::20080616>>
DN 134:147847
TI Combinatorial solid-phase synthesis of multivalent cyclic neoglycopeptides
AU Wittmann, Valentin; Seeberger, Sonja
CS Institut für Organische Chemie, Johann Wolfgang Goethe-Universität,
Frankfurt, 60439, Germany
SO Angewandte Chemie, International Edition (2000), 39(23),
4348-4352
CODEN: ACIEF5; ISSN: 1433-7851
PB Wiley-VCH Verlag GmbH
DT Journal
LA English
OS CASREACT 134:147847
IT 324532-92-5DP, resin-bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of multivalent cyclic neoglycopeptides using solid-phase
synthesis)
RN 324532-92-5 HCAPLUS
CN β -Alaninamide, N2-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N5-[[[(2Z)-4-
[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-
2-butenyl]oxy]carbonyl]-L-ornithylglycyl-L-alanyl-N6-[[[(2Z)-4-[[3,4,6-tri-
O-acetyl-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-2-
butenyl]oxy]carbonyl]-D-lysyl-N5-[[[(2Z)-4-[[3,4,6-tri-O-acetyl-2-
(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-2-butenyl]oxy]carbonyl]-
L-ornithyl-D-valyl-L- α -glutamyl-N-(3-hydroxy-9H-xanthen-9-yl)-,
(8 \rightarrow 1)-lactam (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A

AcO

AcO



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file stnguide
COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 0.12 | 430.95 |

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 0.00 | -8.80 |

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 09:24:49 ON 16 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 13, 2008 (20080613/UP).

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

| | | |
|--|------------|---------|
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| FULL ESTIMATED COST | ENTRY | SESSION |
| | 0.06 | 431.01 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL |
| CA SUBSCRIBER PRICE | ENTRY | SESSION |
| | 0.00 | -8.80 |

FILE 'REGISTRY' ENTERED AT 09:25:30 ON 16 JUN 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 15 JUN 2008 HIGHEST RN 1028329-25-0
 DICTIONARY FILE UPDATES: 15 JUN 2008 HIGHEST RN 1028329-25-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\olson\My Documents\e-Red
 Folder\10524048\10524048not2.str



```

chain nodes :
8 9 12
ring nodes :
1 2 3 4 5 6
chain bonds :
1-8 8-9 9-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 1-8 2-3 3-4 4-5 5-6 8-9 9-12

```

G1:O,C

G2:C,S

G3:O,S,N

G4:C,O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 12:CLASS

L19 STRUCTURE UPLOADED

=> s l19 sss full

FULL SEARCH INITIATED 09:26:10 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1437076 TO ITERATE

69.6% PROCESSED 1000000 ITERATIONS

726968 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.05

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**

 BATCH **COMPLETE**

PROJECTED ITERATIONS: 1437076 TO 1437076

PROJECTED ANSWERS: 1041659 TO 1047757

L20 726968 SEA SSS FUL L19

=> s l19 sub=116

116 IS NOT A VALID L#

L-numbers must be in the range L1-L999.

ENTER SUBSET L# OR (END):116

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full

FULL SUBSET SEARCH INITIATED 09:26:53 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 1553 TO ITERATE

100.0% PROCESSED 1553 ITERATIONS

1328 ANSWERS

SEARCH TIME: 00.00.01

L21 1328 SEA SUB=L16 SSS FUL L19

=> s l16 not l21

L22 2260 L16 NOT L21

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

221.38

652.39

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-8.80

FILE 'HCAPLUS' ENTERED AT 09:27:22 ON 16 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jun 2008 VOL 148 ISS 25

FILE LAST UPDATED: 15 Jun 2008 (20080615/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l21

L23 752 L21

=> s l18 and l21

L24 752 L21

96 L18 AND L21

=> file stnguide

COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |

FULL ESTIMATED COST

| | |
|------|--------|
| 2.69 | 655.08 |
|------|--------|

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |

CA SUBSCRIBER PRICE

| | |
|------|-------|
| 0.00 | -8.80 |
|------|-------|

FILE 'STNGUIDE' ENTERED AT 09:27:46 ON 16 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jun 13, 2008 (20080613/UP).

=>

=>

=> d l24 l2-14 ti abs bib hitstr

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L24 ANSWER 12 OF 96 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Synthesis of a building block for phosphonate analogs of moenomycin A12 from D-tartaric acid

AB An approach for the synthesis of moenomycin A12 C-glycoside partial structures is reported based on allyltin chemical An approach for the synthesis of moenomycin A12 C-glycoside partial structures is reported based on allyltin chemical

AN 2001:246287 HCAPLUS <<LOGINID::20080616>>


DN 135:19848



TI Synthesis of a building block for phosphonate analogs

of moenomycin A12 from D-tartaric acid
 AU Zahra, J.; Hennig, L.; Findeisen, M.; Welzel, P.; Muller, D.; Sheldrick,
 W. S.
 CS Fakultat für Chemie und Mineralogie Johannisallee 29, Universität Leipzig,
 Leipzig, D-04103, Germany
 SO Tetrahedron Letters (2001), 42(16), 2969-2972
 CODEN: TELEAY; ISSN: 0040-4039
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 OS CASREACT 135:19848
 IT 162895-32-1P, moenomycin A12
 RL: PNU (Preparation, unclassified); PREP (Preparation)
 (synthesis of a building block for phosphonate
 analogs of moenomycin A12 from D-tartaric acid)
 RN 162895-32-1 HCAPLUS
 CN α -D-Galactopyranuronamide, O- β -D-glucopyranosyl-(1 \rightarrow 6)-O-
 [O-[N-(2-hydroxy-5-oxo-1-cyclopenten-1-yl)- β -D-
 galactopyranuronamidoyl]-(1 \rightarrow 4)-2-(acetylamino)-2,6-dideoxy- β -
 D-glucopyranosyl-(1 \rightarrow 4)]-O-2-(acetylamino)-2-deoxy- β -D-
 glucopyranosyl-(1 \rightarrow 2)-, 3-carbamate 1-[(2R)-2-carboxy-2-
 [[(2Z,6E,13E)-3,8,8,14,18-pentamethyl-11-methylene-2,6,13,17-
 nonadecatetraenyl]oxy]ethyl hydrogen phosphate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


PAGE 1-A





RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 13 OF 96 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Combinatorial solid-phase synthesis of multivalent cyclic neoglycopeptides
GI



AB The authors have synthesized an 18-member library of carbohydrate-substituted cyclic peptides of the type cyclo[Boc-Lys-Pro-Lys(R)-Ala-Pro-Gly-Leu-Glu]-Bal-NH₂ [BOC = (CH₃)₃CO₂(O); Bal = β-alanine; R = 2-acetylamino-2-deoxy-3,4,6-tri-O-acetyl-β-D-glucopyranosyl, which was connected via -(Z)-CH₂CH:CHCH₂OC(O)- linker to side-chain amino groups of the cyclic peptide]. Using split-mix bead solid-phase synthesis techniques, up to three R groups were introduced to the cyclic peptide to test for directed multivalent activity in lectin binding. The urethane-type linker for sugar attachment gave virtually quant. yield, and allowed cleavage of the sugars from the cyclic peptide scaffold to allow for automated microsequencing of the scaffold under standard conditions. Using H₂C:CHCH₂OC(O), OCH₂CH:CH₂, and Ddv (I) as protecting groups for, resp., the N-terminal Lys, the C-terminal Glu side-chain, and the side-chain amino groups to be sugar-substituted, the synthesis allowed on-bead cyclization and side-chain substitution using selective deprotection reactions.



AN 2000:894358 HCAPLUS <<LOGINID:20080616>>
 DN 134:147847
 TI Combinatorial solid-phase synthesis of multivalent cyclic neoglycopeptides
 AU Wittmann, Valentin; Seeberger, Sonja
 CS Institut für Organische Chemie, Johann Wolfgang Goethe-Universität, Frankfurt, 60439, Germany
 SO Angewandte Chemie, International Edition (2000), 39(23), 4348-4352
 CODEN: ACIEF5; ISSN: 1433-7851
 PB Wiley-VCH Verlag GmbH
 DT Journal
 LA English
 OS CASREACT 134:147847
 IT 324532-92-5DP, resin-bound
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of multivalent cyclic neoglycopeptides using solid-phase synthesis)
 RN 324532-92-5 HCAPLUS
 CN β-Alaninamide, N₂-[[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N₅-[[[(2Z)-4-[[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-2-butenyl]oxy]carbonyl]-L-ornithylglycyl-L-alanyl-N₆-[[[(2Z)-4-[[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-2-butenyl]oxy]carbonyl]-D-lysyl-N₅-[[[(2Z)-4-[[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-2-butenyl]oxy]carbonyl]-L-ornithyl-D-valyl-L-α-glutamyl-N-(3-hydroxy-9H-xanthen-9-yl)-, (8→1)-lactam (9CI) (CA INDEX NAME)



Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A

AcO

AcO






RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


- L24 ANSWER 14 OF 96 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Parallel synthesis of muramyl peptides derivatives
 AB A symposium report. 46 N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP) derivs. in which organic acids were sep. linked to the C terminal of MDP or to the C terminal of MDP's isomer N-acetyl isomuramyl-L-alanyl-D-isoglutamine through a bridge were prepared for study of structure-activity relationship. The small library of MDP derivs. on solid phase with multipin kits was constructed.
 AN 2000:842865 HCAPLUS <<LOGINID::20080616>>
 DN 134:178795
 TI Parallel synthesis of muramyl peptides derivatives
 AU Zhang, Suo-De; Liu, Gang; Xia, Su-Quan; Ding, Zhen-Kai
 CS Institute of Pharmacology and Toxicology, Academy of Military Medical Science, Beijing, 100850, Peop. Rep. China
 SO Peptides: Biology and Chemistry, Proceedings of the Chinese Peptide Symposium, 5th, Lanzhou, China, July 14-17, 1998 (2000), Meeting Date 1998, 198-201. Editor(s): Hu, Xiao-Yu; Wang, Rui; Tam, James P. Publisher: Kluwer Academic Publishers, Dordrecht, Neth.
 CODEN: 69AQX6
 DT Conference
 LA English
 IT 15892-26-9 39524-05-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (solid phase synthesis of muramyl peptides derivs.)
 RN 15892-26-9 HCAPLUS
 CN α -Muramic acid, N-acetyl-1-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 39524-05-5 HCAPLUS
 CN α -Isomuramic acid, N-acetyl-1-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 325728-17-4P 325728-18-5P 325728-19-6P
 325728-20-9P 325728-21-0P 325728-22-1P
 325728-23-2P 325728-24-3P 325728-25-4P
 325728-26-5P 325728-27-6P 325728-28-7P
 325728-29-8P 325728-30-1P 325728-31-2P
 325728-32-3P 325728-33-4P 325728-34-5P
 325728-35-6P 325728-36-7P 325728-37-8P
 325728-38-9P 325728-39-0P 325728-40-3P
 325728-41-4P 325728-42-5P 325728-43-6P
 325728-44-7P 325728-45-8P 325728-46-9P
 325728-47-0P 325728-48-1P 325728-49-2P
 325728-50-5P 325728-51-6P 325728-52-7P
 325728-53-8P 325728-54-9P 325728-55-0P
 325728-56-1P 325728-57-2P 325728-58-3P
 325728-59-4P 325728-60-7P 325728-61-8P
 325728-62-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (solid phase synthesis of muramyl peptides derivs.)


RN 325728-17-4 HCAPLUS
 CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutamyl-N6-[1-(4-chlorobenzoyl)-5-methoxy-1H-indol-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 325728-18-5 HCAPLUS
 CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-[2-(3-benzoylphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 325728-19-6 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(1H-indol-3-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 325728-20-9 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(1H-benzimidazole-2-carbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 325728-21-0 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-[2-(6-methoxy-2-naphthalenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 325728-22-1 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-[2-(acetyloxy)benzoyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 325728-23-2 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(1H-indazol-3-ylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 325728-24-3 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminyl-N6-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 325728-25-4 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminyl-N6-(9H-xanthen-9-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-26-5 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminyl-N6-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B






RN 325728-27-6 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D-α-glutaminy-N6-[(4-methoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-30-1 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutamyl-N6-(2-fluorobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 325728-31-2 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(1-oxo-3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.
Double bond geometry unknown.



RN 325728-32-3 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-[[3,4-dihydro-4-oxo-3-[4-(phenylmethoxy)phenyl]-7-quinazoliny]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 325728-33-4 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutamyl-N6-[2-(2,5-dioxo-1-pyrrolidinyl)-5-methoxybenzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 325728-34-5 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-[N-acetyl-1-O-(phenylmethyl)- α -isomuramoyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 325728-35-6 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(hydroxydiphenylacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 325728-36-7 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(3,4,5-trihydroxybenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 325728-37-8 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(4-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 325728-38-9 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(2-quinoliny carbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 325728-39-0 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D-α-glutamyl-N6-(1-oxo-2,4-hexadienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.







RN 325728-40-3 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(diphenylacetyl)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 325728-41-4 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(4-nitrobenzoyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 325728-42-5 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(3-hydroxy-1-oxobutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 325728-43-6 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminyln-6-(2-[1,1'-biphenyl]-4-yl-1-oxohexyl)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 325728-44-7 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminyln-6-(9-anthracenylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 325728-45-8 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(hydroxyphenylacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 325728-46-9 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminyl-N6-[N-acetyl-1-O-(phenylmethyl)- α -muramoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-47-0 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminyl-N6-[(9-hydroxy-9H-fluoren-9-yl)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-48-1 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D-α-glutaminy-N6-(2-iodobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-49-2 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy1-N6-[[1-(4-chlorobenzoyl)-5-methoxy-1H-indol-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-50-5 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy1-N6-[2-(3-benzoylphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 325728-51-6 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy1-N6-(1H-indol-3-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-A



PAGE 1-B





RN 325728-54-9 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy1-N6-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-55-0 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy-1-N6-[(4-methoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-56-1 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy-1-N6-[(2R)-2-(6-methoxy-2-naphthalenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-57-2 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy1-N6-[2-(acetyloxy)benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-58-3 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy-N6-(1H-indazol-3-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-59-4 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy-N6-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-60-7 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy1-N6-(4-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-61-8 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy1-N6-(2-quinolinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 325728-62-9 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy1-N6-(1-oxo-2,4-hexadienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> file registry
```

COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |

FULL ESTIMATED COST

| | |
|------|--------|
| 0.24 | 674.42 |
|------|--------|

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |

CA SUBSCRIBER PRICE

0.00 -11.20

FILE 'REGISTRY' ENTERED AT 09:30:37 ON 16 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

```
STRUCTURE FILE UPDATES: 15 JUN 2008 HIGHEST RN 1028329-25-0
DICTIONARY FILE UPDATES: 15 JUN 2008 HIGHEST RN 1028329-25-0
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Documents and Settings\eolson\My Documents\e-Red
Folder\10524048\10524048mainnot2.str

L25 STRUCTURE UPLOADED

=> s l25

SAMPLE SEARCH INITIATED 09:30:54 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 197806 TO ITERATE

1.0% PROCESSED 2000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**

BATCH **INCOMPLETE**

PROJECTED ITERATIONS: 3929988 TO 3982252

PROJECTED ANSWERS: 291366 TO 306008

L26 50 SEA SSS SAM L25

=> d his

(FILE 'HOME' ENTERED AT 09:07:06 ON 16 JUN 2008)

FILE 'REGISTRY' ENTERED AT 09:07:15 ON 16 JUN 2008

L1 STRUCTURE UPLOADED

L2 50 S L1

L3 76450 S L1 SSS FULL

L4 STRUCTURE UPLOADED

L5 STRUCTURE UPLOADED

L6 STRUCTURE UPLOADED

L7 42345 S L4 SUB=L3 FULL

L8 9767 S L5 SUB=L7 FULL

L9 3925 S L6 SUB=L8 FULL

FILE 'CAPLUS' ENTERED AT 09:17:01 ON 16 JUN 2008

L10 1698 S L9

FILE 'STNGUIDE' ENTERED AT 09:17:10 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:18:05 ON 16 JUN 2008

L11 122010 S MONOSACCH? OR (BUILDING BLOCK) OR (LIBRARY)

L12 196 S L10 AND L11

L13 160 S L12 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'STNGUIDE' ENTERED AT 09:18:11 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:19:08 ON 16 JUN 2008

FILE 'STNGUIDE' ENTERED AT 09:19:09 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:19:31 ON 16 JUN 2008

```

FILE 'STNGUIDE' ENTERED AT 09:20:03 ON 16 JUN 2008

FILE 'REGISTRY' ENTERED AT 09:22:10 ON 16 JUN 2008
L14      STRUCTURE UPLOADED
L15      337 S L14 SUB=L9 FULL
L16      3588 S L9 NOT L15

FILE 'HCAPLUS' ENTERED AT 09:23:09 ON 16 JUN 2008
L17      1520 S L16
L18      142 S L17 AND L13

FILE 'STNGUIDE' ENTERED AT 09:23:32 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:23:47 ON 16 JUN 2008

FILE 'STNGUIDE' ENTERED AT 09:23:48 ON 16 JUN 2008

FILE 'STNGUIDE' ENTERED AT 09:24:49 ON 16 JUN 2008

FILE 'REGISTRY' ENTERED AT 09:25:30 ON 16 JUN 2008
L19      STRUCTURE UPLOADED
L20      726968 S L19 SSS FULL
L21      1328 S L19 SUB=L16 FULL
L22      2260 S L16 NOT L21

FILE 'HCAPLUS' ENTERED AT 09:27:22 ON 16 JUN 2008
L23      752 S L21
L24      96 S L18 AND L21

FILE 'STNGUIDE' ENTERED AT 09:27:46 ON 16 JUN 2008

FILE 'HCAPLUS' ENTERED AT 09:28:13 ON 16 JUN 2008

FILE 'STNGUIDE' ENTERED AT 09:28:15 ON 16 JUN 2008

FILE 'REGISTRY' ENTERED AT 09:30:37 ON 16 JUN 2008
L25      STRUCTURE UPLOADED
L26      50 S L25

=> s l26 sub=12
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full
FULL SUBSET SEARCH INITIATED 09:31:21 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 11 TO ITERATE

100.0% PROCESSED 11 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01


L27      7 SEA SUB=L2 SSS FUL L25

=> d l27 scan

L27 7 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN  $\alpha$ -D-Mannopyranoside, phenylmethyl 2-(acetylamino)-2-deoxy-,
MF 3-acetate
C17 H23 N O7

Absolute stereochemistry.

```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2


L27 7 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN L-Serinamide, N-acetyl-L-leucyl-L-tyrosyl-L-arginyl-L-alanyl-L-
 histidylglycyl-L-valyl-L-leucyl-O-[2-(acetylamino)-2-deoxy-β-D-
 glucopyranosyl]-L-seryl-L-cysteinylglycyl-L-tyrosyl-
 SQL 13
 MF C73 H112 N20 O23 S

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



L27 7 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN L-Aspartic acid, L-arginyl-L-valyl-L-seryl-O-[2-(acetylamino)-2-deoxy-
 β-D-glucopyranosyl]-L-seryl-L-glutaminyl-L-α-aspartyl-L-
 tyrosylglycyl-L-arginyl-
 SQL 10
 MF C55 H88 N18 O24


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s 122 not 17
L28 0 L22 NOT L7

=> s 122 not 127
L29 2260 L22 NOT L27

=> file hcaplus
COST IN U.S. DOLLARS

| | |
|------------|---------|
| SINCE FILE | TOTAL |
| ENTRY | SESSION |
| 44.86 | 719.28 |

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

| | |
|------------|---------|
| SINCE FILE | TOTAL |
| ENTRY | SESSION |
| 0.00 | -11.20 |

CA SUBSCRIBER PRICE

FILE 'HCAPLUS' ENTERED AT 09:34:05 ON 16 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jun 2008 VOL 148 ISS 25
FILE LAST UPDATED: 15 Jun 2008 (20080615/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> s 129
L30 872 L29

=> s 124 and 129
872 L29
L31 19 L24 AND L29

=> d 131 1-19 ti abs bib hitstr


L31 ANSWER 1 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Study of glycosylation with N-trichloroacetyl-D-glucosamine derivatives in the syntheses of the spacer-armed pentasaccharides sialyl lacto-N-neotetraose and sialyl lacto-N-tetraose, their fragments, and analogues
AB The syntheses of 2-aminoethyl glycosides of the pentasaccharides Neu5Ac- α (2 \rightarrow 3)-Gal- β (1 \rightarrow 4)-GlcNAc- β (1 \rightarrow 3)-Gal- β (1 \rightarrow 4)-Glc and Neu5Ac- α (2 \rightarrow 3)-Gal- β (1 \rightarrow 3)-GlcNAc- β (1 \rightarrow 3)-Gal- β (1 \rightarrow 4)-Glc, their asialo di-, tri-, and tetrasaccharide fragments, and analogs included a systematic study of glycosylation with variously protected mono- and disaccharide donors derived from N-trichloroacetyl-D-glucosamine of galactose, lactose, and lactosamine glycosyl acceptors bearing benzoyl protection around the OH group to be glycosylated. Despite the low reactivity of these acceptors, stereospecificity and good to excellent yields were obtained with NIS-TfOH-activated thioglycoside donors of such type, or with AgOTf-activated glycosyl bromides, while other promoters, as well as a trichloroacetimidate donor, were less effective, and a β -acetate donor was inactive. In NIS-TfOH-promoted glycosylation with the thioglycosides, the use of TfOH in catalytic amount led to rapid formation of the corresponding oxazoline, but the quantity of TfOH necessary for further efficient coupling with an acceptor depended on the reactivity of the donor, varying from 0.07 equiv for a 3,6-di-O-benzylated monosaccharide derivative to 2.1 equiv for a peracetylated disaccharide one. In the glycosylation products, the N-trichloroacetyl group was easily converted into N-acetyl by alkaline hydrolysis followed by N-acetylation.
AN 2001:780036 HCAPLUS <<LOGINID::20080616>>
DN 136:184030
TI Study of glycosylation with N-trichloroacetyl-D-glucosamine derivatives in the syntheses of the spacer-armed pentasaccharides sialyl lacto-N-neotetraose and sialyl lacto-N-tetraose, their fragments, and analogues
AU Sherman, Andrei A.; Yudina, Olga N.; Mironov, Yuri V.; Sukhova, Elena V.; Shashkov, Alexander S.; Menshov, Vladimir M.; Nifantiev, Nikolay E.
CS N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, 119991, Russia
SO Carbohydrate Research (2001), 336(1), 13-46
CODEN: CRBRAT; ISSN: 0008-6215
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 136:184030
IT 65730-00-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(study of glycosylation with N-trichloroacetyl-D-glucosamine derivs. in the syntheses of spacer-armed pentasaccharides)
RN 65730-00-9 HCAPLUS
CN β -D-Glucopyranoside, 2-propenyl 2-(acetilamino)-2-deoxy-3-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 399035-90-6P 399036-09-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (study of glycosylation with N-trichloroacetylD-glucosamine derivs. in
 the syntheses of spacer-armed pentasaccharides)
 RN 399035-90-6 HCAPLUS
 CN β -D-Glucopyranoside, ethyl 2-deoxy-3,6-bis-O-(phenylmethyl)-1-thio-2-
 [(trichloroacetyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 399036-09-0 HCAPLUS
 CN β -D-Glucopyranoside, 2-propen-1-yl 2-(acetylamino)-2-deoxy-3-O-
 (phenylmethyl)-, 6-benzoate (CA INDEX NAME)


Absolute stereochemistry.



IT 399035-94-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (study of glycosylation with N-trichloroacetylD-glucosamine derivs. in
 the syntheses of spacer-armed pentasaccharides)
 RN 399035-94-0 HCAPLUS


CN β -D-Glucopyranoside, ethyl O-2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl-(1 \rightarrow 3)-O-[2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl-(1 \rightarrow 6)]-2-deoxy-1-thio-2-[(trichloroacetyl)amino]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 2 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Preparation of oligosaccharide lipid-A analogs as antitumor and
immunostimulating agents
GI



AB New synthetic sugar Lipid-A analogs I wherein at least one of R1-R5 is selected from RCONHCH[R'NHCO]CH₂CO-, RCH[X](CH₂)mAOCHR'(CH₂)nB-, RAOCHR'(CH₂)mBOCHR"(CH₂)nL-, where the remaining R1-R5 AR IDP H, R, COR, RCONHCH[R'NHCO]CH₂CO-, RCH[X](CH₂)mAOCHR'(CH₂)nB-, RAOCHR'(CH₂)mBOCHR"(CH₂)nL-, RCH(X)(CH₂)mA-, RAOCHR'(CH₂)mB-, where each R, R', R" is independently selected from the group consisting of -CH-, -C(=O)- and -C(=S) groups; each X is independently selected from the group consisting of -OH, -SH, -NH, and-halogen; m and n are independently selected from the range of integers between 0 and 10 inclusive, X1 and X are -O- or -NH-, Y1 and Y2 are independently selected from the group consisting of -OH, -OP(O)(OH), -COOH, -OSOH, -CH(COOH) and -OP(O)(OH)(OCHCHNH), Z is H, -CHE, or -CHMG, where E is hydrogen, halogen, OH, NH, OSOH, SOH, P(O)(OH) or OP(O)(OH); M is -O-, -S-, -OC(=O), -SC(=O), -OC(=S)-, or -NHC(=O); G is -hydrogen, or a substituted or unsubstituted, branched or linear, saturated or unsatd. C-2 aliphatic hydrocarbon. or a physiol. acceptable salt thereof. Liposome

formulations containing totally synthetic components such as synthetic Lipid-A and synthetic lipopeptide derived from tumor-associated MUC1 mucin are described along with their therapeutic utility. Comparative test results of immunostimulating properties and toxicity of Lipid-A analogs are included. Thus, 2-deoxy-4-O-phosphono-2-[(3S)-3-tetradecanamido-4-nonylamino-4-oxo-butanamido]-3-O-tetradecanoyl-D-glucopyranose was prepared and tested in mice as antitumor and immunostimulating agent (CPM = m22).

AN 2001:380597 HCAPLUS <<LOGINID:20080616>>

DN 134:367137

TI Preparation of oligosaccharide lipid-A analogs as antitumor and immunostimulating agents

IN Jiang, Zi-Hua; Bach, Mimi; Yalamati, Damayanthi; Koganty, Rao; Longenecker, Michael

PA Biomira, Inc., Can.

SO PCT Int. Appl., 155 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|--------------|
| PI | WO 2001036433 | A2 | 20010525 | WO 2000-US31281 | 20001115 <-- |
| | WO 2001036433 | A3 | 20020510 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2396744 | A1 | 20010525 | CA 2000-2396744 | 20001115 <-- |
| | AU 2001017647 | A | 20010530 | AU 2001-17647 | 20001115 <-- |
| | AU 780577 | B2 | 20050407 | | |
| | EP 1232168 | A2 | 20020821 | EP 2000-980380 | 20001115 <-- |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | JP 2003514824 | T | 20030422 | JP 2001-538922 | 20001115 <-- |
| PRAI | US 1999-164928P | P | 19991115 | <-- | |
| | WO 2000-US31281 | W | 20001115 | <-- | |
| OS | MARPAT 134:367137 | | | | |
| IT | 230966-79-7P 339316-72-2P 339316-86-8P 339316-91-5P 339316-94-8P 339317-06-5P 339317-13-4P 339317-21-4P 339317-29-2P 339317-37-2P 339317-38-3P | | | | |
| | RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) | | | | |
| | (preparation of oligosaccharide lipid A analogs as antitumor and immunostimulating agents) | | | | |
| RN | 230966-79-7 HCAPLUS | | | | |
| CN | α -D-Glucopyranoside, 2-propenyl 2-deoxy-6-O-(phenylmethyl)-2-[[[(2,2,2-trichloroethoxy)carbonyl]amino]-, 3-[(3R)-3-[(1-oxotetradecyl)oxy]tetradecanoate] (9CI) (CA INDEX NAME) | | | | |


Absolute stereochemistry. Rotation (+).



RN 339316-72-2 HCAPLUS

CN α -D-Glucopyranoside, phenylmethyl 2-deoxy-2-[[3S]-4-(nonylamino)-1,4-dioxo-3-[(1-oxotetradecyl)amino]butyl]amino]-6-O-(phenylmethyl)-, 3-tetradecanoate (CA INDEX NAME)



Absolute stereochemistry. Rotation (+).



RN 339316-86-8 HCAPLUS

CN β -D-Glucopyranoside, phenylmethyl 2-deoxy-6-O-[2-deoxy-2-[[3R]-1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]amino]-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-6-O-(phenylmethyl)- β -D-glucopyranosyl]-2-[[3R]-1-oxo-3-[(1-oxohexadecyl)oxy]tetradecyl]amino]-3,4-bis-O-(phenylmethyl)- (CA INDEX NAME)



Absolute stereochemistry. Rotation (-).



RN 339316-91-5 HCAPLUS

CN β -D-Glucopyranoside, phenylmethyl 2-deoxy-6-O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-2-[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-6-O-(phenylmethyl)- β -D-glucopyranosyl]-2-[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-3,4-bis-O-(phenylmethyl)- (CA INDEX NAME)



Absolute stereochemistry. Rotation (-).



RN 339316-94-8 HCAPLUS

CN β -D-Glucopyranoside, phenylmethyl 2-deoxy-6-O-[2-deoxy-2-[[[(3S)-4-(nonylamino)-1,4-dioxo-3-[(1-oxotetradecyl)amino]butyl]amino]-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]- β -D-glucopyranosyl]-2-[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-3,4-bis-O-(phenylmethyl)-(CA INDEX NAME)



Absolute stereochemistry. Rotation (-).



RN 339317-06-5 HCAPLUS

CN β -D-Glucopyranoside, phenylmethyl 2-deoxy-6-O-[2-deoxy-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-2-[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-6-O-(phenylmethyl)- β -D-glucopyranosyl]-2-[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-4-O-(phenylmethyl)-3-O-2-propen-1-yl]- (CA INDEX NAME)



Absolute stereochemistry. Rotation (-).



RN 339317-13-4 HCAPLUS

CN β -D-Glucopyranoside, phenylmethyl 2-deoxy-6-O-[2-deoxy-2-[[[(3S)-4-(nonylamino)-1,4-dioxo-3-[(1-oxotetradecyl)amino]butyl]amino]-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-6-O-(phenylmethyl)- β -D-glucopyranosyl]-2-[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-4-O-(phenylmethyl)-, 3-[(3R)-3-(phenylmethoxy)tetradecanoate] (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 339317-21-4 HCAPLUS

CN α -D-Glucopyranoside, phenylmethyl 2-deoxy-2-[[[(2,2,2-trichloroethoxy)carbonyl]amino]-, 3-[(3R)-3-(phenylmethoxy)tetradecanoate]
(CA INDEX NAME)


Absolute stereochemistry.



RN 339317-29-2 HCAPLUS

CN α -D-Glucopyranoside, 2-propen-1-yl 2-deoxy-6-O-(phenylmethyl)-2-[[2,2,2-trichloroethoxy]carbonylamino]-, 3-[(3R)-3-(dodecyloxy)tetradecanoate] (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 339317-37-2 HCAPLUS

CN α -D-Glucopyranoside, phenylmethyl 2-deoxy-3-O-(phenylmethyl)-2-[[2,2,2-trichloroethoxy]carbonylamino]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 339317-38-3 HCAPLUS


CN α -D-Glucopyranoside, phenylmethyl 2-deoxy-2-[[2,2,2-trichloroethoxy]carbonylamino]-3-O-(phenylmethyl)-1-oxotetradecyl]-3-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




L31 ANSWER 3 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Parallel synthesis of muramyl peptides derivatives
 AB A symposium report. 46 N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP) derivs. in which organic acids were sep. linked to the C terminal of MDP or to the C terminal of MDP's isomer N-acetyl isomuramyl-L-alanyl-D-isoglutamine through a bridge were prepared for study of structure-activity relationship. The small library of MDP derivs. on solid phase with multipin kits was constructed.
 AN 2000:842865 HCAPLUS <<LOGINID::20080616>>
 DN 134:178795
 TI Parallel synthesis of muramyl peptides derivatives
 AU Zhang, Suo-De; Liu, Gang; Xia, Su-Quan; Ding, Zhen-Kai
 CS Institute of Pharmacology and Toxicology, Academy of Military Medical Science, Beijing, 100850, Peop. Rep. China
 SO Peptides: Biology and Chemistry, Proceedings of the Chinese Peptide Symposium, 5th, Lanzhou, China, July 14-17, 1998 (2000), Meeting Date 1998, 198-201. Editor(s): Hu, Xiao-Yu; Wang, Rui; Tam, James P. Publisher: Kluwer Academic Publishers, Dordrecht, Neth. CODEN: 69AQX6
 DT Conference
 LA English
 IT 15892-26-9 39524-05-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (solid phase synthesis of muramyl peptides derivs.)
 RN 15892-26-9 HCAPLUS
 CN α -Muramic acid, N-acetyl-1-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 39524-05-5 HCAPLUS
 CN α -Isomuramic acid, N-acetyl-1-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 325728-17-4P 325728-18-5P 325728-19-6P
 325728-20-9P 325728-21-0P 325728-22-1P
 325728-23-2P 325728-24-3P 325728-25-4P
 325728-26-5P 325728-27-6P 325728-28-7P
 325728-29-8P 325728-30-1P 325728-31-2P
 325728-32-3P 325728-33-4P 325728-34-5P
 325728-35-6P 325728-36-7P 325728-37-8P
 325728-38-9P 325728-39-0P 325728-40-3P
 325728-41-4P 325728-42-5P 325728-43-6P
 325728-44-7P 325728-45-8P 325728-46-9P
 325728-47-0P 325728-48-1P 325728-49-2P
 325728-50-5P 325728-51-6P 325728-52-7P
 325728-53-8P 325728-54-9P 325728-55-0P
 325728-56-1P 325728-57-2P 325728-58-3P
 325728-59-4P 325728-60-7P 325728-61-8P
 325728-62-9P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (solid phase synthesis of muramyl peptides derivs.)


RN 325728-17-4 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-[1-(4-chlorobenzoyl)-5-methoxy-1H-indol-3-yl]acetyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-18-5 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-[2-(3-benzoylphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-19-6 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(1H-indol-3-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-20-9 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D-α-glutaminy-N6-(1H-benzimidazole-2-carbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-21-0 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-[2-(6-methoxy-2-naphthalenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-22-1 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-[2-(acetyloxy)benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-23-2 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D-α-glutaminy-N6-(1H-indazol-3-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-24-3 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-25-4 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(9H-xanthen-9-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-26-5 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-27-6 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-[(4-methoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 325728-28-7 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(3-methylbenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 325728-29-8 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-[3-(3-nitrophenyl)-1-oxo-2-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.







RN 325728-30-1 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(2-fluorobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-31-2 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(1-oxo-3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.

PAGE 1-A



PAGE 1-B





RN 325728-32-3 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-[1,3,4-dihydro-4-oxo-3-[4-(phenylmethoxy)phenyl]-7-quinazoliny]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-33-4 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-[2-(2,5-dioxo-1-pyrrolidinyl)-5-methoxybenzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-34-5 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-[N-acetyl-1-O-(phenylmethyl)- α -isomuramoyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 325728-35-6 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(hydroxydiphenylacetyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 325728-36-7 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(3,4,5-trihydroxybenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 325728-39-0 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D-α-glutamyl-N6-(1-oxo-2,4-hexadienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.







RN 325728-40-3 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(diphenylacetyl)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 325728-41-4 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(4-nitrobenzoyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 325728-42-5 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutamyl-N6-(3-hydroxy-1-oxobutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 325728-43-6 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminyln-6-(2-[1,1'-biphenyl]-4-yl-1-oxohexyl)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 325728-44-7 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminyln-6-(9-anthracenylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 325728-45-8 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(hydroxyphenylacetyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 325728-46-9 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-[N-acetyl-1-O-(phenylmethyl)- α -muramoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-47-0 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-[(9-hydroxy-9H-fluoren-9-yl)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-48-1 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)muramoyl]-L-alanyl-D- α -glutaminy-N6-(2-iodobenzoyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-49-2 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy1-N6-[[1-(4-chlorobenzoyl)-5-methoxy-1H-indol-3-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-50-5 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy1-N6-[2-(3-benzoylphenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-51-6 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy1-N6-(1H-indol-3-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-52-7 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy-N6-(1H-benzimidazole-2-carbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-53-8 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy-N6-(9H-xanthen-9-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-54-9 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy1-N6-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-55-0 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy-1-N6-[(4-methoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-56-1 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy-1-N6-[(2R)-2-(6-methoxy-2-naphthalenyl)-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-57-2 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy1-N6-[2-(acetyloxy)benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-58-3 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy1-N6-(1H-indazol-3-ylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 325728-59-4 HCAPLUS


CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy1-N6-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 325728-60-7 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D-
α-glutaminy1-N6-(4-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 325728-61-8 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy1-N6-(2-quinolinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 325728-62-9 HCAPLUS

CN L-Lysinamide, N-[N-acetyl-1-O-(phenylmethyl)isomuramoyl]-L-alanyl-D- α -glutaminy1-N6-(1-oxo-2,4-hexadienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 4 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Efficient Synthesis of a Stereochemically Defined Carbohydrate Scaffold:
Carboxymethyl 2-Acetamido-6-Azido- 4-O-Benzyl-2-deoxy- α -D-
Glucopyranoside

GI




I

AB The authors have described a highly efficient synthesis of a monosaccharide scaffold I with appropriate orientation of the functional group triad for the generation of broad spectrum libraries. Two key steps in this synthesis are the regioselective ring opening of a benzylidene acetal to obtain the 4-O-benzyl derivative using H₃B·NMe₃/Me₂BBr, and efficient oxidation of a 1-O-allyl to 1-O-carboxymethyl group in the presence of a benzyl ether as well as an azido functionality.

AN 2000:758802 HCAPLUS <<LOGINID::20080616>>


DN 134:56892
 TI Efficient Synthesis of a Stereochemically Defined Carbohydrate Scaffold:
 Carboxymethyl 2-Acetamido-6-Azido- 4-O-Benzyl-2-deoxy- α -D-
 Glucopyranoside
 AU Ghosh, Manuka; Dulina, Richard G.; Kakarla, Ramesh; Sofia, Michael J.
 CS Intercardia Research Laboratories, Cranbury, NJ, 08852, USA
 SO Journal of Organic Chemistry (2000), 65(24), 8387-8390
 CODEN: JOCEAH; ISSN: 0022-3263
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 134:56892
 IT 224964-75-4P 251324-18-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (efficient synthesis of carboxymethyl acetamidoazidobenzyl
 deoxy- α -D-glucopyranoside, a stereochem. defined carbohydrate
 scaffold)
 RN 224964-75-4 HCAPLUS
 CN α -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-6-O-
 (phenylmethyl)-, 3-acetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 251324-18-2 HCAPLUS
 CN α -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-4-O-
 (phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L31 ANSWER 5 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI combinatorial libraries and solid phase synthesis of glycosides and

glycopeptides

GI



I



II

AB A compound of structure I wherein X is O or S; Z is O or NH; Y is COOH, COOR2, CH2OR3, CH3, or CHsY2(3-s) where Y2 is F, Cl, Br or I, and s is 0, 1, or 2 or Y and one of ZR4 and OR5 are linked to form a 6-membered cyclic acetal; Q = (CH2)n; p is 0 or 1; m is 0 or 1; n is 1 or 2. A library of compds. of structure II wherein X is O or S; Q = (CH2)n; A1 is a residue of an α -amino acid attached through a terminal amino, a peptide residue comprising residues of from 2 to 10 α -amino acids and attached through a terminal amino, R1 O, R1S, R1, R1NH or R1N-alkyl; A2 is a residue of an α -amino acid attached through a terminal carboxyl, a peptide residue comprising residues of from 2 to 10 α -amino acids and attached through a terminal carboxyl, R2SO2, R2NHCO, R2OP(O)(OR6), R2P(O)(OR6) or R2, or A2, A3 and N combine to form a nitrogen heterocycle; A3 is hydrogen when A3 is not combined with A2 and N; A4 is OR4, NHR4, CH2OR4 or CH3; A5 is O, NH or N-alkyl; p, q and r are independently 0 or 1; Y1 and Y2 are independently O or CH2; each of L1 and L2 is independently a difunctional alkyl, aryl, aralkyl, alkanoyl, aroyl or aralkanoyl group; L3 is a single bond, CH2, carbonyl, OP(O)(OR7), NHP(O)(OR7), P(O)(OR7). Thus, solid phase preparation of Me 4-azido-4-deoxy-3O-benzoyl-2'-O-carboxymethyl- α -D-fucopyranoside using peptide-bound resins is reported.

AN 1999:764164 HCAPLUS <<LOGINID::20080616>>

DN 132:12479

TI combinatorial libraries and solid phase synthesis of glycosides and glycopeptides

IN Sofia, Michael J.; Jain, Rakesh K.; Vaughan, Andrew; Gange, David M.; Ghosh, Manuka

PA Incara Pharmaceuticals Corp., USA

SO PCT Int. Appl., 106 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----|--|------|----------|-----------------|--------------|
| PI | WO 9961583 | A2 | 19991202 | WO 1999-US12032 | 19990528 <-- |
| | WO 9961583 | A3 | 20000406 | | |
| W: | AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: | GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |

PRAI US 1998-87072P

P 19980528 <--

OS MARPAT 132:12479


IT 224964-75-4P 251324-18-2P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (combinatorial libraries and solid phase synthesis of glycosides and glycopeptides)

RN 224964-75-4 HCAPLUS

CN α -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-6-O-(phenylmethyl)-, 3-acetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 251324-18-2 HCAPLUS

CN α -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-4-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



TI Combinatorial library and solid-phase preparation of
lipoglycopeptides as bactericides
GI



I

AB Combinatorial library and solid-phase preparation of
lipoglycopeptides of formula PSL (P = peptide; S = sugar, L = lipid) as
bactericides are reported. Thus, lipoglycopeptide I was prepared and tested
as protein bactericide (IC50 = 2.4 .-. 0.2 µg/mL).
AN 1997:640561 HCAPLUS <<LOGINID::20080616>>
DN 127:293557
OREF 127:57387a,57390a
TI Combinatorial library and solid-phase preparation of
lipoglycopeptides as bactericides
IN Sofia, Michael; Allanson, Nigel; Chen, Anna; Liu, Dashan; Chan, Tin Yau
PA Transcell Technologies, Inc., USA
SO PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|--------------|
| PI | WO 9734623 | A1 | 19970925 | WO 1997-US4637 | 19970321 <-- |
| | W: | | | | |
| | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: | | | | |
| | GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2249323 | A1 | 19970925 | CA 1997-2249323 | 19970321 <-- |
| | AU 9723411 | A | 19971010 | AU 1997-23411 | 19970321 <-- |
| | EP 934076 | A1 | 19990811 | EP 1997-916162 | 19970321 <-- |
| | R: | | | | |
| | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | JP 2000507246 | T | 20000613 | JP 1997-533750 | 19970321 <-- |
| PRAI | US 1996-13777P | P | 19960321 | <-- | |
| | US 1996-24528P | P | 19960826 | <-- | |
| | WO 1997-US4637 | W | 19970321 | <-- | |
| IT | 196698-49-4P 196698-50-7P 196698-51-8P | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) | | | | |
| | (combinatorial library and solid phase preparation of lipoglycopeptides as bactericides) | | | | |

RN 196698-49-4 HCAPLUS

CN D-Alanine, N-(N-acetyl-1-O-dodecyl-β-muramoyl)-L-alanyl-D-α-glutaminy-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

OH

RN 196698-50-7 HCAPLUS

CN D-Alanine, N-(N-acetyl-1-O-dodecyl-β-muramoyl)-L-alanyl-D-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 196698-51-8 HCAPLUS


CN D-Alanine, N-(N-acetyl-1-O-dodecyl-β-muramoyl)glycyl-D-α-glutaminy-L-lysyl-D-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



IT 63064-54-0P 196697-20-8P 196697-23-1P
 196697-34-4P 196697-35-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (combinatorial library and solid phase preparation of
 lipoglycopeptides as bactericides)
 RN 63064-54-0 HCAPLUS
 CN α -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-3,6-bis-O-
 (phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 196697-20-8 HCAPLUS

CN α -Muramic acid, N-acetyl-1-O-2-propenyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196697-23-1 HCAPLUS

CN α -Muramic acid, N-acetyl-1-O-2-propenyl-6-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196697-34-4 HCAPLUS

CN α -Normuramic acid, N-acetyl-1-O-2-propenyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 196697-35-5 HCAPLUS

CN α -Normuramic acid, N-acetyl-1-O-2-propenyl-6-O-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 184910-81-4P 184910-82-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(combinatorial library and solid phase preparation of
lipoglycopeptides as bactericides)

RN 184910-81-4 HCAPLUS


CN L-Alanine, N-[N-acetyl-1-O-[2-(dodecylamino)-2-oxoethyl]- α -muramoyl]-
L-alanyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 184910-82-5 HCAPLUS
 CN L-Alanine, N-[N-acetyl-6-O-[2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]-1-O-[2-(dodecylamino)-2-oxoethyl]- α -muramoyl]-L-alanyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L31 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Lipid A and related compounds. XXXIII. Synthesis and structure-activity relationships of N-acylated L-serine or L-threonine-containing D-glucosamine derivatives as mimics of lipid A disaccharide

GI



AB Four novel N-acylated L-serine or L-threonine-containing non-phosphorylated D-glucosamine derivs. structurally corresponding to the lipid A disaccharide backbone were synthesized. Compds. I (R1 = CH3, R2 = R3 = R4 = H; R1 = CH3, R2 = CH3(CH2)12CO, R3 = R4 = H; R1 = R2 = R3 = R4 = H) exhibited potent mitogenic activity. Among the threonine-linked lipid A analogs, serine-linked lipid A analogs, and homoserine-linked lipid A analogs, the serine compds. showed the most potent mitogenic activity.

AN 1997:427322 HCAPLUS <<LOGINID::20080616>>

DN 127:109122


OREF 127:21051a,21054a

TI Lipid A and related compounds. XXXIII. Synthesis and structure-activity relationships of N-acylated L-serine or L-threonine-containing D-glucosamine derivatives as mimics of lipid A disaccharide

AU Miyajima, Keisuke; Gomi, Noriaki; Ikeda, Kiyoshi; Achiwa, Kazuo


CS School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, 422,
Japan
SO Chemical & Pharmaceutical Bulletin (1997), 45(6), 1089-1093
CODEN: CPBTAL; ISSN: 0009-2363
PB Pharmaceutical Society of Japan
DT Journal
LA English
IT 192462-69-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological
study); PREP (Preparation)
(synthesis and structure-activity relationships of N-acylated L-serine
or L-threonine containing D-glucosamine derivs. as mimics of lipid A
disaccharide)
RN 192462-69-4 HCAPLUS
CN L-Threonine, O-[2-deoxy-2-[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]
amino]-3-O-(1-oxotetradecyl)-β-D-glucopyranosyl]-N-(1-oxotetradecyl)-
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 192462-80-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(synthesis and structure-activity relationships of N-acylated L-serine
or L-threonine containing D-glucosamine derivs. as mimics of lipid A
disaccharide)
RN 192462-80-9 HCAPLUS
CN L-Threonine, O-[2-deoxy-2-[[[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]
amino]-4,6-bis-O-(phenylmethyl)-β-D-glucopyranosyl]-N-(1-
oxotetradecyl)-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 8 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Substituted oligosaccharide as substrates and inhibitors for
glycosyltransferases and glycosidases and their enzymic synthesis
AB Substituted oligosaccharides that are substrates for some
glycosyltransferases and glycosidases and inhibitors for others are prepared
for use in the control of enzymic synthesis of oligosaccharides. The
system uses an acceptor saccharide; a donor monosaccharide; an
activating nucleotide suitable for the monosaccharide; an
activated donor monosaccharide regenerating system; a
pyrophosphate scavenger, and a glycosyltransferase. Several rounds of
enzymic synthesis can be conducted as necessary. (2R)-methyl-(3R,4R,5S)-
trihydroxypiperidine(I) was prepared by the aldolase-catalyzed reaction of
HCl-hydrolyzed (R)-3-azido-2-hydroxypropanal di-Et acetal and
dihydroxyacetone phosphate. I was then reduced with Pd in the presence of
HCHO to yield (1,2R)-dimethyl-(3R,4R,5S)-trihydroxypiperidine (II) or
oxidized with H2O2 to give (1,2R)-dimethyl-(3R,4R,5S)-trihydroxypiperidine
oxide (III). I inhibited brewer's yeast α -glucosidase and sweet
almond β -glucosidase with K_i 's of 1.56×10^{-3} and 7.8×10^{-4}
M resp. II inhibited brewer's yeast α -glucosidase and sweet almond
 β -glucosidase with K_i 's of 1.78×10^{-3} and 1.4×10^{-4} M resp.
III inhibited brewer's yeast α -glucosidase and sweet almond
 β -glucosidase with K_i 's of 6.95×10^{-3} and 1.49×10^{-3} M
resp.

AN 1993:186950 HCAPLUS <<LOGINID:20080616>>

DN 118:186950

OREF 118:31992a

TI Substituted oligosaccharide as substrates and inhibitors for
glycosyltransferases and glycosidases and their enzymic synthesis

IN Wong, Chi Huey; Ichikawa, Yoshitaka; Shen, Gwo Jenn

PA Scripps Research Institute, USA

SO PCT Int. Appl., 157 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 8

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|--|------|----------|-----------------|--------------|
| PI | WO 9216640 | A1 | 19921001 | WO 1992-US2178 | 19920317 <-- |
| | W: AU, CA, JP | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE | | | | |
| | US 5278299 | A | 19940111 | US 1991-670701 | 19910318 <-- |


| | | | | |
|--|---------|----------|-----------------|--------------|
| CA 2106301 | A1 | 19920919 | CA 1992-2106301 | 19920317 <-- |
| CA 2106301 | C | 19990406 | | |
| AU 9216680 | A | 19921021 | AU 1992-16680 | 19920317 <-- |
| AU 668505 | B2 | 19960509 | | |
| EP 576592 | A1 | 19940105 | EP 1992-909519 | 19920317 <-- |
| EP 576592 | B1 | 20000531 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE | | | | |
| JP 06505638 | T | 19940630 | JP 1992-508819 | 19920317 <-- |
| JP 3476455 | B2 | 20031210 | | |
| AT 193551 | T | 20000615 | AT 1992-909519 | 19920317 <-- |
| US 5461143 | A | 19951024 | US 1994-219242 | 19940329 <-- |
| US 5593887 | A | 19970114 | US 1995-476685 | 19950607 <-- |
| US 5759823 | A | 19980602 | US 1995-472877 | 19950607 <-- |
| US 6168934 | B1 | 20010102 | US 1998-72958 | 19980505 <-- |
| PRAI US 1991-670701 | A | 19910318 | <-- | |
| US 1991-707600 | A | 19910530 | <-- | |
| US 1991-738211 | A | 19910730 | <-- | |
| US 1992-852409 | A | 19920316 | <-- | |
| WO 1992-US2178 | A | 19920317 | <-- | |
| US 1992-889652 | B1 | 19920526 | <-- | |
| US 1994-219242 | A3 | 19940329 | <-- | |
| US 1995-472877 | A1 | 19950607 | <-- | |
| OS MARPAT 118:186950 | | | | |
| IT 67816-88-0P | | | | |
| RL: PREP (Preparation) | | | | |
| (preparation of, enzymic) | | | | |
| RN 67816-88-0 | HCAPLUS | | | |
| CN α -D-Glucopyranoside, methyl 2-(acetylamino)-2-deoxy-3-O-2-propenyl- | | | | |
| (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.



| | | | |
|--|--------------|--------------|--------------|
| IT | 136882-32-1P | 136882-33-2P | 136882-34-3P |
| RL: PREP (Preparation) | | | |
| (preparation of, in preparation oligosaccharides) | | | |
| RN | 136882-32-1 | HCAPLUS | |
| CN β -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-, 3-(methyl carbonate) (9CI) (CA INDEX NAME) | | | |


Absolute stereochemistry.



RN 136882-33-2 HCAPLUS

CN β -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-,
3-(2-propenyl carbonate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 136882-34-3 HCAPLUS

CN β -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-3-O-
(methoxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L31 ANSWER 9 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Building units of oligosaccharides. CIV. Synthesis of branched tetrasaccharide and pentasaccharide structures of N-glycoproteins methylated at 4'-OH of the branching unit.

AB The tetrasaccharide α -D-Manp-(1 \rightarrow 3)[α -D-Manp-(1 \rightarrow 6)]-4-O-methyl- β -D-Manp-(1 \rightarrow 4)-D-GlcNAc and the pentasaccharide β -D-GlcpNAc-(1 \rightarrow 2)- α -D-Manp-(1 \rightarrow

3) [α -D-Manp-(1 \rightarrow 6)]-4-O-methyl- β -D-Manp-(1 \rightarrow 4)-D-GlcNAc were synthesized by adding the resp. functionalized building blocks. The compds. are useful for studies of the substrate specificities of GlcNAc transferases I and II in the biosynthesis of N-linked oligosaccharides, resp. In addition, an effective synthesis for the β -glycosidically linked building block β -D-Manp-(1 \rightarrow 4)- α -D-GlcNAc was developed. The trichloroacetimidate method was particularly successful for synthesizing these glycosidic linkages.

AN 1993:59982 HCAPLUS <<LOGINID::20080616>>

DN 118:59982

OREF 118:10775a,10778a

TI Building units of oligosaccharides. CIV. Synthesis of branched tetrasaccharide and pentasaccharide structures of N-glycoproteins methylated at 4'-OH of the branching unit.

AU Paulsen, Hans; Wilkens, Roland; Brockhausen, Inka

CS Inst. Org. Chem., Univ. Hamburg, Hamburg, W-2000/13, Germany

SO Liebigs Annalen der Chemie (1992), (12), 1303-313

CODEN: LACHDL; ISSN: 0170-2041

DT Journal

LA English

OS CASREACT 118:59982


IT 55287-49-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(glycosidation of, by benzylideneglucopyranosyl trichloroacetimidate derivative)

RN 55287-49-5 HCAPLUS

CN α -D-Glucopyranoside, phenylmethyl 2-(acetylamino)-2-deoxy-3,6-bis-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




IT 143669-62-9P 143669-68-5P 143730-17-0P

143730-19-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as acetylglucosaminyl transferase substrate)


RN 143669-62-9 HCAPLUS

CN α -D-Glucopyranose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O-4-O-methyl- β -D-mannopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)




RN 143669-68-5 HCAPLUS

CN α -D-Glucopyranose, 0-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-(α -D-mannopyranosyl-(1 \rightarrow 6))-O-4-O-methyl- β -D-mannopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)




RN 143730-17-0 HCAPLUS

CN β -D-Glucopyranose, 0-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-(α -D-mannopyranosyl-(1 \rightarrow 6))-O-4-O-methyl- β -D-mannopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)



RN 143730-19-2 HCAPLUS

CN β -D-Glucopyranose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O-4-O-methyl- β -D-mannopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)




IT 143669-84-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as key intermediate of acetylglucosaminyl transferase substrates)

RN 143669-84-5 HCAPLUS

CN α -D-Glucopyranoside, phenylmethyl O-2,3,4,6-tetra-O-acetyl- α -D-mannopyranosyl-(1 \rightarrow 6)-O-4-O-methyl-2-O-(phenylmethyl)- β -D-mannopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy-3,6-bis-O-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



L31 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2008 ACS on SIN

TI Preparation of lipid A monosaccharide analogs as immunostimulants and antitumor agents.

GI



AB The title compds. [I; one of R1,R4 = H, P(O)(OH)2, protecting group; the other = P(O)(OH)2; one of R2,R3 = (halo-, HO-, or C6-20 aliphatic acyloxy-substituted) C6-20 aliphatic acyl and the other = halo-, HO-, or C6-20 aliphatic acyloxy-substituted C6-20 aliphatic acyl, (halo-, HO-, or C6-20 aliphatic acyloxy-substituted) C6-20 alkyl], possessing macrophage-activating activity (no data), are prepared. Thus, amidation of I (R1 = allyl, R2 = R3 = H, R4R5 = CMe2) (preparation given) with (R)-3-benzyloxymyristic acid in CH2Cl2 containing DCC followed by esterification with (±)-syn-2-fluoro-3-benzyloxycarboxyloxymyristic acid in CH2Cl2 containing DCC and 4-dimethylaminopyridine gave I [R1 = allyl, R2 = (R)-Me(CH2)10CH(OCH2Ph)CH2CO, R3 = (±)-Me(CH2)10CH(OCO2CH2Ph)CHFCO, R4R5 = CMe2]. The latter was treated with 1,5-cyclooctadiene-bis[methyldiphenylphosphine]iridium hexafluorophosphate and then H2, iodine, and pyridine to give I (R1 = H; R2-R5 = same as above) which was phosphorylated with (PhCH2O)2P(O)Cl in THF in the presence of BuLi followed by hydrogenolysis over 10% Pd/C to give I [R1 = P(O)(OH)2, R2 = (R)-Me(CH2)10CH(OH)CH2CO, R3 = (±)-Me(CH2)10CH(OH)CHFCO, R4 = R5 = H]. Addnl. 19 I were prepared

AN 1992:59901 HCAPLUS <<LOGINID::20080616>>

DN 116:59901

OREF 116:10385a, 10388a

TI Preparation of lipid A monosaccharide analogs as immunostimulants and antitumor agents.
 IN Shiosaki, Masao; Ishida, Noboru; Kobayashi, Tomoo; Hiraoka, Tetsuo; Akamatsu, Minoru; Nishijima, Masahiro
 PA Sankyo Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 54 pp.
 CODEN: JKXXAF

DI Patent
 LA Japanese
 FAN.CNT 2


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|--------------|
| PI | JP 02256697 | A | 19901017 | JP 1989-321153 | 19891211 <-- |
| | JP 2839921 | B2 | 19981224 | | |
| | DD 295854 | A5 | 19911114 | DD 1990-342041 | 19900625 <-- |
| | SU 1836378 | A3 | 19930823 | SU 1990-4830600 | 19900625 <-- |
| | CN 1052481 | A | 19910626 | CN 1990-106805 | 19900626 <-- |
| | CN 1029405 | B | 19950802 | | |
| | HU 55793 | A2 | 19910628 | HU 1990-3991 | 19900626 <-- |
| | HU 217114 | B | 19991129 | | |
| | CZ 285583 | B6 | 19990915 | CZ 1990-3185 | 19900626 <-- |
| | CA 2019972 | A1 | 19910611 | CA 1990-2019972 | 19900627 <-- |
| | CA 2019972 | C | 20000808 | | |
| | EP 437016 | A2 | 19910717 | EP 1990-307045 | 19900627 <-- |
| | EP 437016 | B1 | 19960501 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE | | | | |
| | AT 137504 | T | 19960515 | AT 1990-307045 | 19900627 <-- |
| | ES 2088970 | T3 | 19961001 | ES 1990-307045 | 19900627 <-- |
| | KR 187302 | B1 | 19990401 | KR 1990-9570 | 19900627 <-- |
| | RU 2076107 | C1 | 19970327 | RU 1992-5052656 | 19920909 <-- |
| | US 5792840 | A | 19980811 | US 1994-280298 | 19940726 <-- |
| | KR 183315 | B1 | 19990401 | KR 1998-37538 | 19980911 <-- |
| PRAI | JP 1988-329964 | A1 | 19881227 | <-- | |
| | JP 1989-321153 | A | 19891211 | <-- | |
| | JP 1990-37339 | A | 19900220 | <-- | |
| | US 1990-539605 | B1 | 19900618 | <-- | |
| | KR 1990-9570 | A | 19900627 | <-- | |

OS MARPAT 116:59901
 IT 132760-36-2P 132760-38-4P 132760-39-5P
 132760-45-3P 132760-46-4P 132760-50-0P
 132791-86-7P 132791-89-0P 132791-91-4P
 132791-94-7P 132791-95-8P 132792-02-0P
 132792-04-2P 132792-05-3P 132828-16-1P
 132831-92-6P 132881-14-2P 132882-51-0P
 132882-54-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as intermediate for antitumor and immunostimulant lipid A analog)


RN 132760-36-2 HCAPLUS
 CN β -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[[2-fluoro-1-oxo-3-[[[(phenylmethoxy)carbonyl]oxy]tetradecyl]amino]-, 3-[3-[[[(phenylmethoxy)carbonyl]oxy]tetradecanoate], [2(2R,3S),3(R)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 132760-38-4 HCAPLUS

CN β -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[[(phenylmethoxy)carbonyl]oxy]tetradecyl]amino]-, 3-[3-(phenylmethoxy)tetradecanoate], [2(2S,3R),3(R)]- (9CI) (CA INDEX NAME)




RN 132760-39-5 HCAPLUS

CN β -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[[(phenylmethoxy)carbonyl]oxy]tetradecyl]amino]-, 3-[3-(phenylmethoxy)tetradecanoate] 6-(phenylmethyl carbonate), [2(2S,3R),3(R)]- (9CI) (CA INDEX NAME)




RN 132760-45-3 HCAPLUS

CN β -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[[1-oxotetradecyl]oxy]tetradecyl]amino]-, 3-tetradecanoate, [R-(R*,S*)]- (9CI) (CA INDEX NAME)




RN 132760-46-4 HCAPLUS

CN β -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-, 6-(phenylmethyl carbonate) 3-tetradecanoate, [R-(R*,S*)]- (9CI) (CA INDEX NAME)



RN 132760-50-0 HCAPLUS


CN β -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-6-O-[(phenylmethoxy)methyl]-, 3-tetradecanoate, [S-(R*,S*)]- (9CI) (CA INDEX NAME)



RN 132791-86-7 HCAPLUS


CN β -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[[[(phenylmethoxy)carbonyl]oxy]tetradecyl]amino]-, 3-[3-[[[(phenylmethoxy)carbonyl]oxy]tetradecanoate] 6-(phenylmethyl carbonate), [2(2R,3S),3(R)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 132791-89-0 HCAPLUS

CN α -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[[[phenylmethoxy]carbonyl]oxy]tetradecyl]amino]-, 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate] 6-(phenylmethyl carbonate), [2(2S,3R),3(R)]- (9CI) (CA INDEX NAME)



RN 132791-91-4 HCAPLUS

CN α -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[[[phenylmethoxy]carbonyl]oxy]tetradecyl]amino]-, 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate], [2(2R,3S),3(R)]- (9CI) (CA INDEX NAME)




RN 132791-94-7 HCAPLUS

CN α -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[1-oxo-3-

(phenylmethoxy)tetradecyl]amino]-3-O-[3-(phenylmethoxy)tetradecyl]-,
[2(R),3(R)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 132791-95-8 HCAPLUS


α-D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[1-oxo-3-(phenylmethoxy)tetradecyl]amino]-6-O-[(phenylmethoxy)methyl]-3-O-[3-(phenylmethoxy)tetradecyl]-, [2(R),3(R)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 132792-02-0 HCAPLUS


β-D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-, 3-[3-(phenylmethoxy)tetradecanoate], [2(R,3S),3(R)]- (9CI) (CA INDEX NAME)



RN 132792-04-2 HCAPLUS

CN β -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2,2-difluoro-1-oxo-3-[[(phenylmethoxy)carbonyl]oxy]tetradecyl]amino]-, 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate] (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 132792-05-3 HCAPLUS


CN β -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2,2-difluoro-1-oxo-3-[[(phenylmethoxy)carbonyl]oxy]tetradecyl]amino]-, 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate] 6-(phenylmethyl carbonate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 132828-16-1 HCAPLUS

CN β -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-6-O-[(phenylmethoxy)methyl]-, 3-[3-(phenylmethoxy)tetradecanoate], [2(2S,3R),3(R)]- (9CI) (CA INDEX NAME)




RN 132831-92-6 HCAPLUS

CN β -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-, 3-tetradecanoate, [S-(R*,S*)]- (9CI)
(CA INDEX NAME)





RN 132881-14-2 HCAPLUS

CN α -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[[[(phenylmethoxy)carbonyl]oxy]tetradecyl]amino]-, 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate] 6-(phenylmethyl carbonate), [2(2R,3S),3(R)]- (9CI) (CA INDEX NAME)




RN 132882-51-0 HCAPLUS

CN α -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[[2-fluoro-1-oxo-3-[[[(phenylmethoxy)carbonyl]oxy]tetradecyl]amino]-, 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate], [2(2S,3R),3(R)]- (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 136882-32-1 HCAPLUS

CN β-D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-, 3-(methyl carbonate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 136882-33-2 HCAPLUS

CN β-D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-, 3-(2-propenyl carbonate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 136882-34-3 HCAPLUS


CN β-D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-3-O-(methoxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L31 ANSWER 12 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Selective pivaloylation of 2-(acetamido)-2-deoxy sugars [Erratum to document cited in CA110(23):213238k]
 AB Errors in the names for compds. 8, 19, and 20 have been corrected The errors were reflected in the index entries.
 AN 1989:614852 HCAPLUS <<LOGINID::20080616>>
 DN 111:214852
 OREF 111:35649a,35652a
 TI Selective pivaloylation of 2-(acetamido)-2-deoxy sugars [Erratum to document cited in CA110(23):213238k]
 AU Ljevakovic, Durdica; Tomic, Srdanka; Tomasic, Jelka
 CS Dep. Radioimmunol., Inst. Immunol., Zagreb, 41000, Yugoslavia
 SO Carbohydrate Research (1989), 191(1), C1
 CODEN: CRBRAT; ISSN: 0008-6215
 DT Journal
 LA English
 IT 3748-32-1 19229-53-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (pivaloylation of (Erratum))
 RN 3748-32-1 HCAPLUS
 CN α -Muramic acid, N-acetyl-1-O-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 19229-53-9 HCAPLUS
 CN α -Isomuramic acid, N-acetyl-1-O-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 120489-44-3P 120489-47-6P 120489-56-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and acetylation of (Erratum))
 RN 120489-44-3 HCAPLUS
 CN α -D-Glucopyranose, 2-(acetylamino)-2-deoxy-, 1,3,6-tris(2,2-
 dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.



RN 120489-47-6 HCAPLUS
 CN α -Muramic acid, N-acetyl-1-O-methyl-, methyl ester,
 6-(2,2-dimethylpropanoate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 120489-56-7 HCAPLUS

CN β -D-Glucopyranose, 2-(acetylamino)-2-deoxy-, 1,3,6-tris(2,2-dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.




IT 120489-33-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, acetylation and enzymic hydrolysis of (Erratum))

RN 120489-33-0 HCAPLUS

CN α -D-Glucopyranoside, methyl 2-(acetylamino)-2-deoxy-,
3,6-bis(2,2-dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.




IT 120489-51-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, acetylation, pivaloylation and enzymic hydrolysis of
(Erratum))



RN 120489-51-2 HCAPLUS

CN β -D-Glucopyranoside, methyl 2-(acetylamino)-2-deoxy-,
3,6-bis(2,2-dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.



L31 ANSWER 13 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Preparation of physiologically active lipid A analogs linked to
 S-containing peptidoglycan analogs.
 GI



AB The title compds. (I; R = Q; R1 = R2 = H; m, n = 8-12; p = 0-22; q = 1-15)
 (II) having physiol. activities (no data) were prepared Esterification of
 2-(trimethylsilyl)ethyl 4-O-[bis(2,2,2-trichloroethyl)phosphono-2-deoxy-3-
 O-tetradecanoyl-2-[(3R)-3-tetradecanoyloxytetradecanamido]-β-D-
 glucopyranoside (III) (preparation given) with succinic anhydride in CH2Cl2
 containing 4-dimethylaminopyridine (DMAP) gave I (R = OH, OR1 =
 β-Me3SiCH2CH2, R2 = CC13CH2, m = n = 12) which was treated with DCC
 in 1,4-dioxane containing concentrated H2SO4 followed by N-acetylmuramic acid
 derivative
 QH (p = 0, q = 10) (IV) (preparation given) to give I (R = Q; OR1, R2, m, n, p,

q = same as above). Stepwise deprotection of the latter by treatment with BF₃·OEt₂ in CH₂Cl₂ to remove Me₃SiCH₂CH₂ group followed by treatment with Zn dust in AcOH to remove the CCl₃CH₂ group gave I (R = Q, R₁ = R₂ = H, m = n = 12, p = 0, q = 10).

AN 1989:534690 HCAPLUS <<LOGINID:20080616>>

DN 111:134690

OREF 111:22563a,22566a

TI Preparation of physiologically active lipid A analogs linked to S-containing peptidoglycan analogs.

IN Hasegawa, Akira; Kiso, Makoto; Morihara, Kazuyuki

PA Toho Pharmaceutical Industries Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 8 pp.


CODEN: JKXXAF

DT Patent

LA Japanese


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|--------------|
| PI | JP 63307896 | A | 19881215 | JP 1987-144457 | 19870609 <-- |
| PRAI | JP 1987-144457 | | 19870609 | <-- | |
| OS | MARPAT 111:134690 | | | | |
| IT | 86704-48-5 89137-05-3 89137-07-5 | | | | |
| | RL: RCT (Reactant); RACT (Reactant or reagent) | | | | |
| | (esterification of, with (tert-butoxycarbonylamino)undecanoic acid) | | | | |
| RN | 86704-48-5 HCAPLUS | | | | |
| CN | D-α-Glutamine, N2-[N-(N-acetyl-1-S-acetyl-1-thio-β-muramoyl)-L-alanyl]-, methyl ester (9CI) (CA INDEX NAME) | | | | |




RN 89137-05-3 HCAPLUS

CN D-α-Glutamine, N2-[N-[N-acetyl-1-S-(1-oxodecyl)-1-thio-β-muramoyl]-L-alanyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 89137-07-5 HCAPLUS

CN D- α -Glutamine, N2-[N-[N-acetyl-1-S-(1-oxooctadecyl)-1-thio- β -muramoyl]-L-alanyl]-, methyl ester (9CI) (CA INDEX NAME)



IT 122565-71-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and amidation of, with (carboxypropanoyl)glucosamine derivative)


RN 122565-71-3 HCAPLUS

CN D- α -Glutamine, N2-[N-[N-acetyl-1-S-acetyl-6-O-(11-amino-1-oxoundecyl)-1-thio- β -muramoyl]-L-alanyl]-, methyl ester, mono(trichloroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 122099-26-7

CMF C33 H57 N5 O12 S




CM 2

CRN 76-03-9

CMF C2 H C13 O2





IT 122078-63-1P 122078-86-8P 122501-68-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and deprotection of)
 RN 122078-63-1 HCAPLUS
 CN D- α -Glutamine, N2-[N-[N-acetyl-1-S-acetyl-6-O-[11-[(1,1-
 dimethylethoxy)carbonyl]amino]-1-oxoundecyl]-1-thio- β -muramoyl]-L-
 alanyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 122078-86-8 HCAPLUS
 CN D- α -Glutamine, N2-[N-[N-acetyl-1-S-acetyl-6-O-[11-[(3-carboxy-1-
 oxopropyl)amino]-1-oxoundecyl]-1-thio- β -muramoyl]-L-alanyl]-,
 5-methyl ester, 6-ester with (R)-2-(trimethylsilyl)ethyl
 2-deoxy-2-[[1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]- β -D-
 glucopyranoside 4-[bis(2,2,2-trichloroethyl) phosphate] 3-tetradecanoate
 (9CI) (CA INDEX NAME)



PAGE 1-A





RN 122501-68-2 HCAPLUS

CN D-α-Glutamine, N2-[N-[N-acetyl-1-S-acetyl-6-O-[11-[(3-carboxy-1-oxopropyl)amino]-1-oxoundecyl]-1-thio-β-muramoyl]-L-alanyl]-, 5-methyl ester, 6-ester with 2-deoxy-2-[[1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-β-D-glucopyranose 4-[bis(2,2,2-trichloroethyl) phosphate] 3-tetradecanoate, (R)- (9CI) (CA INDEX NAME)




IT 122099-30-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and selective silylation of, by tert-butyldimethylsilyl chloride)

RN 122099-30-3 HCAPLUS


CN β-D-Glucopyranoside, 2-(trimethylsilyl)ethyl 2-deoxy-2-[[1-oxo-3-[(1-

Absolute stereochemistry.




| | |
|----|--|
| IT | 122501-63-7P 122501-64-8P 122501-65-9P RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as drug) |
| RN | 122501-63-7 HCAPLUS |
| CN | D- α -Glutamine, N2-[N-[N-acetyl-1-S-acetyl-6-O-[11-[(3-carboxy-1-oxopropyl)amino]-1-oxoundecyl]-1-thio- β -muramoyl]-L-alanyl]-, 5-methyl ester, 6-ester with 2-deoxy-2-[(11-oxo-3-[[1-oxotetradecyl]oxy]tetradecyl)amino]- β -D-glucopyranose 4-(dihydrogen phosphate) 3-tetradecanoate, (R)- (9CI) (CA INDEX NAME) |

PAGE 1-A




PAGE 1-B




RN 122501-64-8 HCAPLUS

CN D-α-Glutamine, N2-[N-[N-acetyl-6-O-[11-[(3-carboxy-1-oxopropyl)amino]-1-oxoundecyl]-1-S-(1-oxodecyl)-1-thio-β-muramoyl]-L-alanyl]-, 5-methyl ester, 6-ester with 2-deoxy-2-[1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-β-D-glucopyranose 4-(dihydrogen phosphate) 3-tetradecanoate, (R)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 122501-65-9 HCAPLUS

CN D-α-Glutamine, N2-[N-[N-acetyl-6-O-[11-[(3-carboxy-1-oxopropyl)amino]-1-oxoundecyl]-1-S-(1-oxooctadecyl)-1-thio-β-muramoyl]-L-alanyl]-, 5-methyl ester, 6-ester with 2-deoxy-2-[1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-β-D-glucopyranose 4-(dihydrogen phosphate) 3-tetradecanoate, (R)- (9CI) (CA INDEX NAME)

PAGE 1-A





L31 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Preparation of physiologically active conjugates of lipid A nonreducing monosaccharide subunit analogs with 1-thiomuramyl dipeptide derivatives

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title conjugates [I; X = O, R = R1 = H; l = 8-12; m = 0-22; n = 1-15; provided that the asym. C's at the 3-position of 2- or 3-substituents in the pyranose ring may have S- or R-configuration], having physiol. activity (no data), were prepared Treatment of I (X = OH, OR = β -OCH2CH2SiMe3, R1 = Cl3CCH2; l = 12) (II) (preparation given) with DCC and concentrated H2SO4 in 1,4-dioxane and reaction of the active intermediate with 1-thiomuramyl dipeptide derivative QH-CF3CO2H (m = 0, n = 10) in MeOH/1,4-dioxane containing Et3N gave 42.2% I (X = O, OR = β -OCH2CH2SiMe3, R1 = CC13CH2, l = 12, m = 0, n = 10). Deprotection of the latter by treatment with BF3·OEt2 in Cl2H2 to remove Me3SiCH2CH2, followed by Zn powder to remove Cl3CCH2 in AcOH, gave I (X = O, R = R1 = H, l = 12, m = 0, n = 10).

AN 1989:515701 HCAPLUS <<LOGINID::20080616>>

DN 111:115701

OREF 111:19407a,19410a

TI Preparation of physiologically active conjugates of lipid A nonreducing monosaccharide subunit analogs with 1-thiomuramyl dipeptide derivatives

IN Hasegawa, Akira; Kiso, Makoto; Morihara, Kazuyuki

PA Toho Pharmaceutical Industries Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DT Patent

LA Japanese


FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------|----------|-----------------|--------------|
| PI | JP 01019098 | A | 19890123 | JP 1987-175766 | 19870714 <-- |
| PRAI | JP 1987-175766 | | 19870714 | | |
| OS | MARPAT 111:115701 | | | | |
| IT | 122099-28-9 | | | | |

RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation of, with (carboxypropanoyl)glucosamine derivative)

RN 122099-28-9 HCAPLUS

CN D- α -Glutamine, N2-[N-[N-acetyl-6-O-(11-amino-1-oxoundecyl)-1-S-(1-oxodecyl)-1-thio- β -muramoyl]-L-alanyl]-, methyl ester (9CI) (CA INDEX NAME)




IT 122078-65-3 122331-26-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation of, with (carboxypropanoyl)glucosamine derivative, in preparation of drug)

RN 122078-65-3 HCAPLUS

CN D- α -Glutamine, N2-[N-[N-acetyl-6-O-(11-amino-1-oxoundecyl)-1-S-(1-oxooctadecyl)-1-thio- β -muramoyl]-L-alanyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 122331-26-4 HCAPLUS


CN D- α -Glutamine, N2-[N-[N-acetyl-1-S-acetyl-6-O-(11-amino-1-oxoundecyl)-1-thio- β -muramoyl]-L-alanyl]-, methyl ester, mono(chloroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 122099-26-7



CMF C33 H57 N5 O12 S





RN 122266-81-3 HCAPLUS

CN D- α -Glutamine, N2-[N-[N-acetyl-1-S-acetyl-6-O-[11-[(3-carboxy-1-oxopropyl)amino]-1-oxoundecyl]-1-thio- β -muramoyl]-L-alanyl]-, 5-methyl ester, 6-ester with 1,5-anhydro-2-deoxy-2-[(3-hydroxy-1-oxotetradecyl)amino]-D-glucitol 4-[bis(2,2,2-trichloroethyl) phosphate] 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate], [2(R),3(R)]- (9CI) (CA INDEX NAME)




IT 122266-75-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and selective silylation of, by tert-butyldimethylsilyl chloride)

RN 122266-75-5 HCAPLUS


CN β -D-Glucopyranoside, 2-(trimethylsilyl)ethyl 2-deoxy-2-[[1-oxo-3-[2-(trimethylsilyl)ethoxy]tetradecyl]amino]-, 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate], [2(R),3(R)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 122266-71-1P 122266-72-2P 122289-57-0P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as drug)
 RN 122266-71-1 HCAPLUS
 CN D- α -Glutamine, N2-[N-[N-acetyl-1-S-acetyl-6-O-[11-[(3-carboxy-1-oxopropyl)amino]-1-oxoundecyl]-1-thio- β -muramoyl]-L-alanyl]-, 5-methyl ester, 6-ester with [2(R),3(R)]-2-deoxy-2-[(3-hydroxy-1-oxotetradecyl)amino]- β -D-glucopyranose 4-(dihydrogen phosphate) 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate] (9CI) (CA INDEX NAME)



PAGE 1-A





RN 122266-72-2 HCAPLUS

CN D- α -Glutamine, N2-[N-[N-acetyl-6-O-[11-[(3-carboxy-1-oxopropyl)amino]-1-oxoundecyl]-1-S-(1-oxooctadecyl)-1-thio- β -muramoyl]-L-alanyl]-, 5-methyl ester, 6-ester with [2(R),3(R)]-2-deoxy-2-[(3-hydroxy-1-oxotetradecyl)amino]- β -D-glucopyranose 4-(dihydrogen phosphate) 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate] (9CI) (CA INDEX NAME)




RN 122289-57-0 HCAPLUS


CN D- α -Glutamine, N2-[N-[N-acetyl-6-O-[11-[(3-carboxy-1-

oxopropyl)amino]-1-oxoundecyl]-1-S-(1-oxodecyl)-1-thio- β -muramoyl]-L-alanyl]-, 5-methyl ester, 6-ester with 2-deoxy-2-[(3-hydroxy-1-oxotetradecyl)amino]- β -D-glucopyranose 4-(dihydrogen phosphate) 3-[3-[(1-oxotetradecyl)oxy]tetradecanoate], [2(R),3(R)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L31 ANSWER 15 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Preparation of lipid A nonreducing monosaccharide analogs linked to peptidoglycan thio analogs having physiological activity


GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *



AB The title compds. (I; R = R1 = H; X = Q; m, n = 8-12; p = 0-22; q = 1-15) (II) having physiol. activities (no data), were prepared Selective S-deacetylation of N-[[2-O-(2-acetamido-1-S-acetyl-2,3-dideoxy-4,6-isopropylidene-1-thio- β -D-glucopyranosyl-3-yl)-D-lactoyl]]-L-alanyl-D-isoglutamine Me ester with NaOMe in MeOH at -20° followed by thioesterification with 11-(tert-butoxycarbonylamino)undecanoic acid in 1,4-dioxane containing DCC, deacetonation with 80% aqueous HOAc at 45°, and esterification with decanoic acid in dioxane containing DCC and a trace of

$$\begin{array}{c} \text{Cl} \\ | \\ \text{Cl}-\text{C}-\text{CO}_2\text{H} \\ | \\ \text{Cl} \end{array}$$

PAGE 1-A




$$\begin{array}{c} \text{--- C --- OMe} \\ || \\ \text{O} \end{array}$$

| | | |
|----|---|---------|
| RN | 121885-18-5 | HCAPLUS |
| CN | D- α -Glutamine, N2-[N-[N-acetyl-1-S-[11-[(3-carboxy-1-oxopropyl)amino]-1-oxoundecyl]-6-O-(1-oxodecyl)-1-thio- β -muramoyl]-L-alanyl]-, 5-methyl ester, 6-ester with 2-(trimethylsilyl)ethyl 2-deoxy-2-[(1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl)amino]- β -D-glucopyranoside 4-bis(2,2,2-trichloroethyl) phosphate] 3-tetradecanoate, (R)- (9CI) (CA INDEX NAME) | |



RN 121885-20-9 HCAPLUS


CN D- α -Glutamine, N2-[N-[N-acetyl-1-S-[11-[(3-carboxy-1-oxopropyl)amino]-1-oxoundecyl]-6-O-(1-oxodecyl)-1-thio- β -muramoyl]-L-alanyl]-, 5-methyl ester, 6-ester with 2-deoxy-2-[[1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]- β -D-glucopyranose 4-[bis(2,2,2-trichloroethyl) phosphate] 3-tetradecanoate, (R)- (9CI) (CA INDEX NAME)




IT 121885-14-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and esterification of, with decanoic acid)


RN 121885-14-1 HCAPLUS

CN D-α-Glutamine, N2-[N-[N-acetyl-1-S-[11-[(1,1-
 dimethylethoxy)carbonyl]amino]-1-oxoundecyl]-1-thio-β-muramoyl]-L-
 alanyl]-, methyl ester (9CI) (CA INDEX NAME)




| | | |
|----|---------------------|---|
| IT | 121897-87-8P | RL: SPN (Synthetic preparation); THU (Therapeutic use); BTOI (Biological study); PREP (Preparation); RES (Uses) |
| RN | | (preparation of, as drug) |
| CN | 121897-87-8 HCAPLUS | D-α-Glutamine, N2-[N-[N-acetyl-1-S-[11-[(3-carboxy-1-oxopropyl)amino]-1-oxoundecyl]-6-O-(1-oxodecyl)-1-thio-β-muramoyl]-L-alanyl-, 5-methyl ester, 6-ester with 2-deoxy-2-[[1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]amino]-β-D-glucopyranose 4-(dihydrogen phosphate) 3-tetradecanoate, (R)- (9CI) (CA INDEX NAME) |





L31 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN
 TI Selective pivaloylation of 2-(acetamido)-2-deoxy sugars
 GI



AB Selective pivaloylation of 2-acetamido-2-deoxy-D-glucose, its Me α - and β -glycosides, and the Me α -glycoside of N-acetyl-D-muramic acid I was studied under various conditions. The structures of the products were established by ¹H-NMR spectroscopy and acetylation. The orders of acylation, HO-6 > HO-3 > HO-1 > HO-4 for 2-acetamido-2-deoxy-D-glucose and HO-6 > HO-3 > HO-4 for its Me glycosides, were established. Me 2-acetamido-2-deoxy-3,6-di-O-pivaloyl- α - and β -D-glucopyranosides and 2-acetamido-2-deoxy-1,3,4,6-tetra-O-pivaloyl-D-glucopyranose were hydrolyzed by rabbit serum esterases.

AN 1989:213238 HCAPLUS <<LOGINID::20080616>>

DN 110:213238

OREF 110:35402h,35403a

TI Selective pivaloylation of 2-(acetamido)-2-deoxy sugars

AU Ljevakovic, Durdica; Tomic, Srdanka; Tomasic, Jelka

CS Dep. Radioimmunol., Inst. Immunol., Zagreb, 41000, Yugoslavia

SO Carbohydrate Research (1988), 182(2), 197-205

CODEN: CRBRAT; ISSN: 0008-6215


DT Journal

LA English

OS CASREACT 110:213238


IT 19229-53-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (pivaloylation of)
 RN 19229-53-9 HCAPLUS
 CN α -Isomuramic acid, N-acetyl-1-O-methyl-, methyl ester (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




IT 120489-44-3P 120489-47-6P 120489-56-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and acetylation of)
 RN 120489-44-3 HCAPLUS
 CN α -D-Glucopyranose, 2-(acetylamino)-2-deoxy-, 1,3,6-tris(2,2-
 dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.



RN 120489-47-6 HCAPLUS
 CN α -Muramic acid, N-acetyl-1-O-methyl-, methyl ester,
 6-(2,2-dimethylpropanoate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 120489-56-7 HCAPLUS

CN β -D-Glucopyranose, 2-(acetylamino)-2-deoxy-, 1,3,6-tris(2,2-dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.




IT 120489-33-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, acetylation and enzymic hydrolysis of)

RN 120489-33-0 HCAPLUS

CN α -D-Glucopyranoside, methyl 2-(acetylamino)-2-deoxy-,
3,6-bis(2,2-dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.




IT 120489-51-2P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation, acetylation, pivaloylation and enzymic hydrolysis of)
 RN 120489-51-2 HCAPLUS
 CN β -D-Glucopyranoside, methyl 2-(acetylamino)-2-deoxy-,
 3,6-bis(2,2-dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.



L31 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Disaccharide

GI For diagram(s), see printed CA Issue.

AB Disaccharides I (R = alkyl, hydroxyalkyl or protected hydroxy alkyl of 7-19 C atoms; R1 = allyl, benzyl, 1-propenyl, trichloroethyl; R2 = H, RCO; R3 = allyl, crotyl, MeOCH2CH2OCH2, MeSCH2, benzyl; R4 = H, ClCH2CO, β -benzoylpropionyl), useful in the preparation of lipid A analogs, were prepared via coupling of the component monosaccharides by oxazoline method. Thus, I [RCO = palmitoyl, R1 = R3 = benzyl, R2 = palmitoyl, R4 = (Cl3CCH2O)2P(O)] was prepared in several steps starting from allyl and benzyl 3,4,6-tri-O-acetyl-2-deoxy-2-palmitamido- β -D-glucopyranoside.

AN 1985:422874 HCAPLUS <<LOGINID:20080616>>

DN 103:22874

OREF 103:3791a,3794a

TI Disaccharide

IN Anderson, Laurens; Nashed, Mina A.

PA Wisconsin Alumni Research Foundation, USA

SO U.S., 14 pp. Cont.-in-part of U.S. Ser. No. 248,692, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|------------------|------|----------|-----------------|--------------|
| PI | US 4495346 | A | 19850122 | US 1982-433055 | 19821006 <-- |
| PRAI | US 1981-248692 | A2 | 19810330 | <-- | |
| OS | MARPAT 103:22874 | | | | |
| IT | 78835-44-6P | | | | |

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation and chloroacetylation of)

RN 78835-44-6 HCAPLUS

CN β -D-Glucopyranoside, 1-propenyl 2-deoxy-2-[(1-oxohexadecyl)amino]-3-O-(phenylmethyl)-, 6-hexadecanoate (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.




IT 78835-47-9P 78835-48-0P 84766-03-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and glycosylation of, with (glucopyrano)oxazoline derivative)
 RN 78835-47-9 HCAPLUS
 CN β -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[(1-oxohexadecyl)amino]-,
 3-hexadecanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 78835-48-0 HCAPLUS
 CN β -D-Glucopyranoside, phenylmethyl 2-deoxy-2-[(1-oxohexadecyl)amino]-,
 3-hexadecanoate (CA INDEX NAME)

Absolute stereochemistry.




RN 84766-03-0 HCAPLUS
 CN β -D-Glucopyranoside, 1-propenyl 2-deoxy-2-[(1-oxohexadecyl)amino]-,
 3-hexadecanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




IT 78835-43-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and isomerization of)
 RN 78835-43-5 HCAPLUS
 CN β -D-Glucopyranoside, 2-propenyl 2-deoxy-2-[(1-oxohexadecyl)amino]-3-O-
 (phenylmethyl)-, 6-hexadecanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 84766-03-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction of, with (glucopyrano)oxazoline derivative)
 RN 84766-03-0 HCAPLUS
 CN β -D-Glucopyranoside, 1-propenyl 2-deoxy-2-[(1-oxohexadecyl)amino]-,
 3-hexadecanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT 78835-42-4P 78835-49-1P 78853-09-5P

84766-02-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, with palmitoyl chloride)

RN 78835-42-4 HCAPLUS

CN β-D-Glucopyranoside, 2-propenyl 2-deoxy-2-[(1-oxohexadecyl)amino]-3-O-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 78835-49-1 HCAPLUS

CN β-D-Glucopyranoside, 2-propenyl 6-O-[4-O-(chloroacetyl)-2-deoxy-6-O-(1-oxohexadecyl)-2-[(1-oxohexadecyl)amino]-3-O-(phenylmethyl)-β-D-glucopyranosyl]-2-deoxy-2-[(1-oxohexadecyl)amino]-, 3-hexadecanoate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 78853-09-5 HCAPLUS

CN β -D-Glucopyranoside, phenylmethyl 6-O-[4-O-(chloroacetyl)-2-deoxy-6-O-(1-oxohexadecyl)-2-[(1-oxohexadecyl)amino]-3-O-(phenylmethyl)- β -D-glucopyranosyl]-2-deoxy-2-[(1-oxohexadecyl)amino]-, 3-hexadecanoate (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 84766-02-9 HCAPLUS

CN β -D-Glucopyranoside, 1-propenyl 2-deoxy-2-[(1-oxohexadecyl)amino]-3-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




IT 78835-52-6P 78853-10-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 78835-52-6 HCAPLUS

CN β -D-Glucopyranoside, phenylmethyl 2-deoxy-6-O-[2-deoxy-6-O-(1-oxohexadecyl)-2-[(1-oxohexadecyl)amino]-3-O-(phenylmethyl)- β -D-glucopyranosyl]-2-[(1-oxohexadecyl)amino]-, 3,4-dihexadecanoate (CA INDEX NAME)


Absolute stereochemistry.



RN 78853-10-8 HCAPLUS

CN β -D-Glucopyranoside, 2-propenyl 2-deoxy-6-O-[2-deoxy-6-O-(1-oxohexadecyl)-2-[(1-oxohexadecyl)amino]-3-O-(phenylmethyl)- β -D-glucopyranosyl]-2-[(1-oxohexadecyl)amino]-, 3,4-dihexadecanoate (9CI) (CA INDEX NAME)




Absolute stereochemistry.



L31 ANSWER 18 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Synthesis of liposaccharide corresponding to fundamental structure of Salmonella-type lipid A

GI



AB The glucopyranose I, which is the fundamental structure of lipid A without the phosphate moiety, was prepared by stepwise introduction of the acyl groups into the disaccharide II. Thus, II prepared by sequential coupling of monosaccharides III (R = Ac, R1 = CH2Ph, R2 = H, R3 = Cl; R = R3 = H, R1 = Bz, R2 = OCH2CH:CH2), acetylation, and N-deacetylation, was treated with Me(CH2)12COCl to give an N,N-dimyristoyl disaccharide, which was saponified to remove the O-acyl groups. Reaction of the product with Me2C(OMe)2 gave semiprotected product IV. The OH groups of IV were acylated with Me(CH2)12COCl and the product hydrolyzed, and selectively reacylated, followed by hydrogenolytic cleavage of the CH2Ph group to give 97% I.

AN 1981:175390 HCAPLUS <<LOGINID::20080616>>

DN 94:175390

OREF 94:28675a,28678a

TI Synthesis of liposaccharide corresponding to fundamental structure of Salmonella-type lipid A

AU Inage, Masaru; Chaki, Haruyuki; Kusumoto, Shoichi; Shiba, Tetsuo

CS Dep. Chem., Osaka Univ., Osaka, 560, Japan

SO Tetrahedron Letters (1980), 21(40), 3889-92

CODEN: TELEAY; ISSN: 0040-4039

DT Journal

LA English


IT 76994-69-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acylation of)

RN 76994-69-9 HCAPLUS


CN D-Glucose, 2-deoxy-6-O-[2-deoxy-2-[(1-oxotetradecyl)amino]-3-O-(phenylmethyl)-β-D-glucopyranosyl]-2-[(1-oxotetradecyl)amino]-, 3,4-ditetradecanoate (CA INDEX NAME)

Absolute stereochemistry.




IT 76994-62-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and coupling reaction of, with monosaccharide)
 RN 76994-62-2 HCAPLUS
 CN β -D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-, 3-benzoate
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 76994-66-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and cyclocondensation reaction of, with dimethoxypropane)
 RN 76994-66-6 HCAPLUS
 CN β -D-Glucopyranoside, 2-propenyl 2-deoxy-6-O-[2-deoxy-2-[(1-oxotetradecyl)amino]-3-O-(phenylmethyl)- β -D-glucopyranosyl]-2-[(1-oxotetradecyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 76994-70-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and hydrogenolysis of)

RN 76994-70-2 HCAPLUS

CN D-Glucose, 2-deoxy-6-O-[2-deoxy-6-O-(1-oxotetradecyl)-2-[(1-oxotetradecyl)amino]-3-O-(phenylmethyl)-β-D-glucopyranosyl]-2-[(1-oxotetradecyl)amino]-, 3,4-ditetradecanoate (CA INDEX NAME)

Absolute stereochemistry.



IT 76994-63-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation, acetylation, and N-deacetylation of)

RN 76994-63-3 HCAPLUS

CN β-D-Glucopyranoside, 2-propenyl 2-(acetylamino)-2-deoxy-6-O-[4,6-di-O-acetyl-2-(acetylamino)-2-deoxy-3-O-(phenylmethyl)-β-D-glucopyranosyl]-, 3-benzoate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L31 ANSWER 19 OF 19 HCAPLUS COPYRIGHT 2008 ACS on STN

TI Introduction of a benzyl protecting group in place of acetyl in partially acetylated sugars

GI



AB Benzylation of partially acetylated amino sugar I (R = Ac, R1 = H) by PhCH2Br gave 70% I (R = PhCH2, R1 = H). Analogous benzylation of II (R = Ac, R1 = H) gave 63% II (R = PhCH2, R1 = H).

AN 1980:215727 HCAPLUS <<LOGINID:20080616>>

DN 92:215727

OREF 92:34967a,34970a

TI Introduction of a benzyl protecting group in place of acetyl in partially acetylated sugars

AU Bovin, N. V.; Zurabian, S. E.; Khorlin, A. Ya.

CS Inst. Bioorg. Khim., Moscow, USSR

SO Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1980), (1), 215-17

CODEN: IASKA6; ISSN: 0002-3353

DT Journal

LA Russian


IT 67535-70-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(benzylation of, by benzyl bromide)

RN 67535-70-0 HCAPLUS

CN α -D-Glucopyranoside, phenylmethyl 2-(acetilamino)-2-deoxy-, 4,6-diacetate (CA INDEX NAME)

Absolute stereochemistry.



IT 73646-11-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 73646-11-4 HCAPLUS

CN α-D-Glucopyranoside, phenylmethyl 2-(acetylamino)-2-deoxy-4,6-bis-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.

